

# Rational optimization of a transcription factor activation domain inhibitor

Received: 21 November 2022

Accepted: 23 October 2023

Published online: 4 December 2023

Check for updates

Shaon Basu<sup>1,12</sup>, Paula Martínez-Cristóbal<sup>2,12</sup>, Marta Frigolé-Vivas<sup>2</sup>, Mireia Pesarrodona<sup>2</sup>, Michael Lewis<sup>2</sup>, Elzbieta Szulc<sup>2</sup>, C. Adriana Bañuelos<sup>3</sup>, Carolina Sánchez-Zarzalejo<sup>2</sup>, Stasé Bielskutė<sup>2</sup>, Jiaqi Zhu<sup>4</sup>, Karina Pombo-García<sup>5</sup>, Carla Garcia-Cabau<sup>2</sup>, Levente Zodi<sup>2</sup>, Hannes Dockx<sup>6</sup>, Jordann Smak<sup>7</sup>, Harpreet Kaur<sup>7</sup>, Cristina Batlle<sup>8</sup>, Borja Mateos<sup>2</sup>, Mateusz Biesaga<sup>2</sup>, Albert Escobedo<sup>2</sup>, Lúdia Bardia<sup>2</sup>, Xavier Verdaguer<sup>2,9</sup>, Alessandro Ruffoni<sup>2</sup>, Nasrin R. Mawji<sup>3</sup>, Jun Wang<sup>3</sup>, Jon K. Obst<sup>3</sup>, Teresa Tam<sup>3</sup>, Isabelle Brun-Heath<sup>2</sup>, Salvador Ventura<sup>8</sup>, David Meierhofer<sup>10</sup>, Jesús García<sup>2</sup>, Paul Robustelli<sup>4</sup>, Travis H. Stracker<sup>7</sup>, Marianne D. Sadar<sup>3</sup>✉, Antoni Riera<sup>2,9</sup>✉, Denes Hnisz<sup>1</sup>✉ & Xavier Salvatella<sup>2,11</sup>✉

Transcription factors are among the most attractive therapeutic targets but are considered largely ‘undruggable’ in part due to the intrinsically disordered nature of their activation domains. Here we show that the aromatic character of the activation domain of the androgen receptor, a therapeutic target for castration-resistant prostate cancer, is key for its activity as transcription factor, allowing it to translocate to the nucleus and partition into transcriptional condensates upon activation by androgens. On the basis of our understanding of the interactions stabilizing such condensates and of the structure that the domain adopts upon condensation, we optimized the structure of a small-molecule inhibitor previously identified by phenotypic screening. The optimized compounds had more affinity for their target, inhibited androgen-receptor-dependent transcriptional programs, and had an antitumorigenic effect in models of castration-resistant prostate cancer in cells and in vivo. These results suggest that it is possible to rationally optimize, and potentially even to design, small molecules that target the activation domains of oncogenic transcription factors.

The genes encoding transcription factors (TFs) are frequently mutated or dysregulated in cancer, and TFs are coveted targets in oncology<sup>1,2</sup>. For example, *TP53*, the most frequently mutated gene in cancer, and *MYC*, the most frequently overexpressed gene in cancer, encode TFs<sup>3</sup>. The rewiring of transcriptional programs is a hallmark of cancer, and oncogenic transcriptional programs of numerous tumor types depend on small subsets of specific TFs<sup>2,4</sup>. Despite their appeal, TFs are considered largely ‘undruggable’ because of the intrinsic disorder of their protein

regions that are essential for transcriptional activity, rendering them challenging targets for structure-based drug discovery<sup>5,6</sup>.

Nuclear hormone receptors, for example the androgen receptor (AR), are TFs that contain a structured ligand-binding domain (LBD), and anti-androgens targeting the LBD are a first-line therapy for the treatment of AR-driven prostate cancer<sup>7,8</sup>. However, approximately 20% of people with prostate cancer progress to castration-resistant prostate cancer (CRPC), a lethal disease that is associated with the

A full list of affiliations appears at the end of the paper. ✉ e-mail: [msadar@bcgsc.ca](mailto:msadar@bcgsc.ca); [antoni.riera@irbbarcelona.org](mailto:antoni.riera@irbbarcelona.org); [hnisz@molgen.mpg.de](mailto:hnisz@molgen.mpg.de); [xavier.salvatella@irbbarcelona.org](mailto:xavier.salvatella@irbbarcelona.org)

emergence of constitutively active AR splice variants. Such splice variants lack a LBD and consist of only a DNA-binding domain (DBD) and an intrinsically disordered activation domain (AD), rendering them insensitive to LBD-targeting anti-androgens<sup>9–12</sup>. Insights into how the ADs of oncogenes function could thus facilitate the development of therapeutic approaches for some of the most lethal cancers.

Recent studies have suggested that IDRs in many cellular proteins mediate liquid–liquid phase separation in vitro and the partitioning of proteins into biomolecular condensates in cells<sup>13,14</sup>. Essentially all human TFs, including AR, contain an IDR, and these regions have recently been shown to contribute to the formation of TF condensates and the partitioning of TFs into heterotypic condensates with transcriptional effectors such as the co-activator Mediator (MED-1) or RNA polymerase II (RNAPII)<sup>15–19</sup>. The molecular basis of TF condensation has been dissected for a small number of TFs and, in all cases, substitutions of amino acids in the IDRs that altered phase separation also altered transcriptional activity<sup>15,20–22</sup>. On the basis of these findings, we hypothesized that gaining insights into the molecular basis of the phase-separation capacity encoded in the IDRs of oncogenic TFs could be exploited to develop small molecules that alter its activity.

To investigate this, we chose to study the sequence and structural determinants of AR phase separation. We discovered that this process is required for nuclear translocation and transactivation. The phase transition is driven by interactions between aromatic residues, distributed throughout the sequence of the AD but particularly concentrated near the C terminus. This region includes a subdomain of the AD that has high helical propensity (transactivation unit 5, Tau-5). Tau-5, which plays a key role in transactivation by the splice variants associated with CRPC, harbors the binding site of EPI-001 (ref. 23), a small-molecular inhibitor of the AR AD discovered by phenotypic screening<sup>24</sup>, a derivative of which is being investigated in clinical trials for CRPC (NCT04421222, NCT05075577). On the basis of how this small molecule interacts with Tau-5, we introduced changes in its chemical structure that have led to substantially improved potency in cells and in human xenografts models of CRPC.

## Results

### AR phase separation is driven by tyrosine residues in the AD

AR forms mesoscale nuclear ‘speckles,’ but their properties have been elusive because of their small size and the nuclear shuttling of the receptor<sup>17–19,25,26</sup>. Using live-cell and fixed imaging, we confirmed that hormone-stimulated endogenous and transgenic AR form clusters (Extended Data Fig. 1). To identify the molecular basis of cluster formation, we studied the clusters formed by AR variants. Full-length AR contains an intrinsically disordered AD, DBD and a C-terminal LBD (Fig. 1a). We found that, in transiently transfected HEK293T cells, full-length AR and the AR-V7 splice variant, which contain the AD and DBD, formed nuclear clusters, but the DBD alone did not (Fig. 1b); as expected, AR-V7 formed nuclear clusters even in the absence of hormone (Extended Data Fig. 2a,b). Of note, higher expression of AR and AR-V7 increased nuclear clustering in HEK293T cells (Extended Data Fig. 2a,b), consistent with the notion that cluster formation involves phase separation and is driven by the AR AD.

To identify the residues of the AR AD that drive cluster formation, we used solution nuclear magnetic resonance (NMR). This technique provides residue-specific information in the absence of structure and is thus well-suited to studying intrinsically disordered proteins<sup>27</sup>. An analysis of the <sup>1</sup>H–<sup>15</sup>N correlation spectrum of purified ARAD revealed that the intensity of the signals of many residues was low, especially when the AR AD was present at high concentrations, suggesting that these residues are involved in transient intermolecular interactions<sup>28</sup>. We analyzed the decrease in signal intensity as a function of position and residue type, which revealed that the residues involved in such interactions are hydrophobic, and many of them are aromatic (Fig. 1c

and Extended Data Fig. 2c,d). These residues are clustered around the <sup>23</sup>FQNLF<sup>27</sup> motif<sup>29</sup> and, especially, in Tau-5 (Extended Data Fig. 2c).


We recently reported that Hsp70 binding to the <sup>23</sup>FQNLF<sup>27</sup> motif of the AR AD increases its solubility in vitro<sup>30</sup>. To avoid interference from this aggregation-prone motif in our ability to study AR AD in vitro, we introduced a substitution in the motif (L26P) that decreases its propensity to aggregate (Extended Data Fig. 2e–h). The AR AD formed droplets in vitro in a concentration-dependent manner (Extended Data Fig. 2i) and the substitution increased the kinetic stability of the droplets (Extended Data Fig. 2j) as well as the rate and degree of recovery in fluorescence recovery after photobleaching experiments (Extended Data Fig. 2k). The AR AD containing substitution L26P, which was introduced only in the experiments performed in vitro, is referred to as wild type\* (WT\*) throughout the study.

To test the contribution of aromatic residues to phase separation, we measured how decreasing the aromatic character of the AR AD affects its cloud point ( $T_c$ ) in vitro<sup>18,31</sup>. We substituted tyrosine residues, the most abundant aromatic amino acid in the AR AD, by serines, thus generating three mutants: 8YtoS, in which the 8 tyrosines closest to the DBD were substituted; 14YtoS, in which the other 14 tyrosines were substituted; and 22YtoS, in which all tyrosines were substituted (Fig. 1c). The substitution of tyrosines by serines led to a reduction in droplet formation (Fig. 1d):  $T_c$  measurements revealed that phase separation of the AR AD occurred at high temperature and ionic strength (Fig. 1e) in the lower critical solution temperature (LCST) regime; therefore, an elevated  $T_c$  is indicative of a reduction in phase separation capacity. We found that none of the YtoS mutants phase-separated at temperatures lower than 60 °C under conditions in which  $T_c = 34$  °C for WT\* AR AD (Fig. 1e,f). To resolve the phase separation capacity of the mutants, we increased protein concentration and ionic strength: we observed that the  $T_c$  measurements of 8YtoS and 14YtoS were 31 °C and 48 °C, respectively; the 22YtoS mutant did not phase separate (Fig. 1f).

Substitution of aromatic residues also compromised the partitioning of the AR AD into heterotypic condensates with transcriptional effector partners. We incubated AR AD proteins with preassembled droplets formed by purified recombinant MED1 IDR, an in vitro model of Mediator condensates<sup>32</sup>, and droplets formed by purified recombinant RNAPII C-terminal domain (CTD), an in vitro model for RNAPII condensates<sup>33</sup>. WT\* AR AD partitioned into both MED1 IDR and RNAPII CTD droplets, whereas the partitioning was reduced by the 22YtoS AR AD mutant (Fig. 1g,h). We modeled heterotypic condensation by mixing MED1 IDR, RNAPII CTD and AR AD proteins. To our surprise, MED1 IDR and RNAPII CTD formed biphasic droplets in which the RNAPII CTD was segregated from the MED1 IDR within the MED1 IDR droplets (Fig. 1i). The addition of 1 μM WT\* AR AD caused the biphasic droplets to blend into a single phase, in which the three components were distributed homogeneously (Fig. 1i,j). This relied on the aromatic character of the AR AD, because the addition of 1 μM 22YtoS led to preferential partitioning into the MED1-IDR liquid phase under the same experimental conditions (Fig. 1i,j and Extended Data Fig. 2l). We attempted to express and purify AR in mammalian cells to study the effect of the YtoS alterations in the full-length receptor, but we could not obtain sufficient amounts of high-quality samples for in vitro experiments.

### AR phase separation is associated with key AR functions

To test the functional relevance of phase separation, we transiently expressed enhanced green fluorescent protein (eGFP)-tagged wild-type full-length AR and mutants containing the 8YtoS, 14YtoS or 22YtoS substitutions in the AD in AR-negative PC3 cells. The expression levels of wild-type and mutant full-length AR were heterogeneous and, in certain cell populations, higher than those of endogenous AR in relevant cell lines (Extended Data Fig. 3a–c). For both wild-type and mutant AR, only cells exhibiting low fluorescence emission were therefore considered for analysis. In contrast to wild-type AR, none of the YtoS mutants formed condensates upon dihydrotestosterone (DHT)




**Fig. 1 | AR phase separation is driven by tyrosine residues in the AD.**

**a**, Predicted structure of AR, colored by structure-prediction confidence from high (blue) to low (yellow). The domains and the native NLS are highlighted. **b**, Live-cell STED imaging of representative ( $n > 3$ ) HEK293T cells transfected with AR constructs tagged with mEGFP. Cells were imaged after treatment with 10 nM DHT for 4 h. Scale bar, 5  $\mu$ m. The dashed line indicates the nuclear periphery. **c**, Intensity of AR AD NMR resonances at different concentrations, relative to the intensity at 25  $\mu$ M. The positions of Tau-1, Tau-5 and <sup>23</sup>FQNLF<sup>27</sup> are highlighted. Green circles indicate residues that were not visible (NV) or not assigned (NA), including residues in polyglutamine (pQ), polyproline (pP) and polyglycine (pG) tracts. Yellow and orange circles represent the positions of tyrosine residues substituted by serines in 8YtoS and 14YtoS; all tyrosine residues were substituted in 22YtoS. **d**, Fluorescence microscopy images of 40  $\mu$ M AR-AD droplets (WT\* and mutants) at 1 M NaCl. Scale bar, 10  $\mu$ m. **e**, Scheme of the phase diagram

of the AR AD and of how  $T_c$  measurements at different solution conditions allow the phase separation capacity of the mutants to be ranked. **f**,  $T_c$  measurements of AR AD (WT\* and the tyrosine to serine mutants), as mean  $\pm$  s.d. of three independent samples, at two different solution conditions. **g**, Representative merged confocal images of 15  $\mu$ M MED1-IDR and 5  $\mu$ M RNAPII-CTD droplets at 20 mM NaCl or 50 mM NaCl, respectively, and 10% ficoll before and after addition of 1  $\mu$ M AR AD (WT\* or 22YtoS). Scale bars, 5  $\mu$ m. **h**, Quantification of AR AD partitioning in MED1-IDR (top) and RNAPII-CTD droplets (bottom), by measuring AR AD fluorescence intensity ( $I(\text{AR AD})$ ). Boxes show the mean and the quartiles of all droplets, represented as colored dots from three replicated images. arb.u., arbitrary units. **i**, Representative ( $n > 3$ ) merged confocal images of MED1-IDR and RNAPII-CTD droplets obtained in 125 mM NaCl and 10% ficoll with and without the addition of 1  $\mu$ M AR AD (WT\* or 22YtoS). Scale bar, 5  $\mu$ m. **j**, Normalized intensity plot of cross-sections from the images shown in **i**.

treatment (Fig. 2a). In addition, although these substitutions do not alter the native nuclear localization signal (NLS)<sup>34</sup> (<sup>629</sup>RKLLK<sup>633</sup>), they decreased the nuclear translocation rate of the AR: when the amount of time that had elapsed since DHT treatment ( $t_{\text{DHT}}$ ) was 60 min, WT AR

was localized within the nucleus, 8YtoS and 14YtoS were distributed roughly evenly between the cytosol and nucleus and 22YtoS remained in the cytosol (Fig. 2a,b). Next, we transfected cells with wild-type and mutant eGFP-AR-V7 variants, which are localized in the nucleus, and



**Fig. 2 | AR phase separation is associated with nuclear translocation and transactivation.** **a**, Fluorescence images from live-cell time-lapse videos of PC3 cells expressing eGFP-AR or the indicated mutants. Scale bar, 10  $\mu$ m. **b**, Quantification of eGFP-AR relative nuclear localization for the cells in **a**, as a function of time elapsed since the addition of 1 nM DHT ( $t_{\text{DHT}}$ ). Error bars represent the s.d. of  $n \geq 15$  cells per time point. **c**, Representative images ( $n > 3$ ) of live PC3 nuclei expressing eGFP-AR-V7 WT or a Tyr to Ser mutant. Scale bar, 5  $\mu$ m. **d**, Quantification of the nuclear granularity for the cells in **c**; each dot represents one nucleus, boxes show the mean of the quartiles of all cells and  $P$  values were calculated using a Dunnett's multiple-comparison test against the WT ( $n \geq 150$  cells per condition). **e**, Selected Gene Ontology (GO) molecular function networks enriched in the top 75 most abundant hits (Bayesian false discovery rate (BFDR)  $\leq 0.02$ , fold change (FC)  $\geq 3$ ) for the indicated bait. Two protein-protein interaction networks are shown: androgen receptor binding (for WT)

and structural constituent of the nuclear pore (for 22YtoS). The line thickness corresponds to the strength of published data supporting the interaction, generated from STRING (string-db.org). Additional GO results are provided in Extended Data Fig. 3h and Supplementary Data Table 1. **f**, Representative results of PLAs in DHT-treated PC3 cells using the indicated antibodies are shown in cyan, with DAPI staining in magenta ( $n > 3$ ). Streptavidin (strep.) labeling is shown in green, with DAPI in blue (far right) in DHT-treated PC3 cells. The boxes correspond to magnified regions of the images, that illustrate the differences in interactions between WT AR and 22YtoS. Scale bars, 10  $\mu$ m. **g**, Transcriptional activity (average  $\pm$  s.e.m.) of AR and Tyr to Ser mutants, assessed using a luciferase reporter assay for AR ( $t_{\text{DHT}} = 1$  h, top) or AR-V7 (bottom) in HEK293 cells. Empty stands for empty vector, and  $P$  were calculated using a Dunnett's multiple-comparison test against the WT ( $n = 3$ , top;  $n = 4$ , bottom).

measured cluster formation (Fig. 2c). We observed a decrease of the spatial variance of fluorescence intensity, that is granularity, in cells expressing the 8YtoS, 14YtoS or 22YtoS mutants, indicating that the propensity of these cells to form clusters was reduced (Fig. 2c,d and Extended Data Fig. 3d).

To probe the mechanistic basis of reduced translocation of phase-separation-deficient AR mutants, we mapped the interactomes of WT and 22YtoS full-length AR using proximity-dependent BioID-mass spectrometry (BioID-MS), a technique to systematically identify the interactions of a specific protein in living cells. The WT AR and the 22YtoS mutant were fused to a FLAG-tagged Mini-TurboID (MTID) enzyme and introduced into PC3 cells using a lentiviral vector. The addition of biotin for 1 h led to increased protein labeling, demonstrating that the MTID enzyme was functional (Extended Data Fig. 3e). We collected samples for BioID-MS before and after 60 minutes of DHT treatment ( $t_{\text{DHT}} = 60$  min) and a significance analysis of interactome quantification (SAINTq), a sampling method to assign confidence scores to protein-protein interactions, revealed that many proteins were enriched after DHT stimulation in cells expressing WT

AR (Extended Data Fig. 3f,g). Enrichment analysis (STRING) identified enriched proteins in categories related to transcription, including a number of proteins that have been established to interact with the AR (Fig. 2e, Extended Data Fig. 3h and Supplementary Data Table 1). By contrast, fewer proteins were identified in 22YtoS cells, with little overlap with the WT AR proteins (Extended Data Fig. 3h,i): enrichment analysis of 22YtoS cells uncovered enriched proteins in several categories related to nuclear transport. Five nucleoporins were identified among the top 75 most enriched proteins (Fig. 2e, Extended Data Fig. 3h and Supplementary Data Table 1). To validate these observations, we performed proximity ligation assays (PLAs) for several of the top hits, including the SWI-SNF component ARID1A, the Mediator component MED1 and NUP153, in both WT and AR-mutant cells. There was an evident PLA signal for WT AR in association with MED1 and with ARID1A, whereas no such interaction was observed for the 22YtoS mutant (Fig. 2f); by contrast, the 22YtoS mutant, but not WT AR, exhibited an interaction with NUP153 in the perinuclear space (Fig. 2f).

We measured the transcriptional activity of both AR and AR-V7 in cells that had been transiently co-transfected with a luciferase reporter

gene driven by an AR-dependent promoter. We found that substitutions of tyrosines in the AR AD led to a reduction of the transcriptional activity of both full-length AR and the AR-V7 splice variant (Fig. 2g).

Finally, we investigated the dependency of gene expression by AR-V7 on the aromatic character of the AR AD. As expected, for the 22YtoS mutant, gene expression was greatly reduced relative to that of WT AR-V7 and substituting all tyrosines with phenylalanines, another aromatic residue, restored gene expression levels to those obtained for WT AR-V7 (Extended Data Fig. 3j–l). Taken together, these results indicate that AR aromatic mutants with reduced phase separation have a lower nuclear translocation rate, increased association with the nuclear pore and reduced gene expression and thus transcriptional activity.

### Short transient helices enhance AR phase separation

Transcriptional activation involves interactions between AD motifs—also known as activation units—and members of the transcriptional machinery<sup>35,36</sup>. Some motifs are known to fold into  $\alpha$ -helices when interacting<sup>37,38</sup>. Therefore, we tested whether such motifs in the AR AD contribute to its phase separation behavior. We identified seven regions with helical propensity in the AR AD using NMR. These included the flanking region of the polyglutamine (pQ) tract starting at position 58 and the<sup>179</sup>LKDIL<sup>183</sup> motif in the Tau-1 region (Fig. 3a)<sup>39,40</sup>. To map the Tau-5 region, which has low peak intensity in the spectrum of full-length AR AD, we performed NMR on a Tau-5 fragment (Tau-5\*), which confirmed the high helical propensity of the<sup>397</sup>WAAAAAQ<sup>403</sup> motif (Fig. 3a)<sup>41</sup>. Previous work has shown that the<sup>23</sup>FQNL<sup>27</sup> motif forms an  $\alpha$ -helix when interacting with the AR LBD<sup>29</sup> in an interaction known as the N/C interaction. Our previous NMR experiments have shown that the<sup>433</sup>WHTLF<sup>437</sup> motif in Tau-5 forms a helix when interacting with TFIIF and have identified two additional motifs,<sup>232</sup>DNAKELCKA<sup>240</sup> and<sup>351</sup>LDEAAAYQS<sup>359</sup>, with weak helical propensity<sup>23,42</sup> (Fig. 3a) that reached approximately 5% in the presence of 5% trifluoroethanol (TFE), a co-solvent that stabilizes the transient helices formed by disordered peptides and proteins<sup>43</sup>.

To investigate the contribution of helical propensity to AR phase separation, we introduced helix-breaking proline substitutions in the AR AD within or immediately adjacent to the helices (Fig. 3b) and measured the  $T_c$  of AR AD proteins (Fig. 3c). We found that L26P (WT\*) increased the  $T_c$  by 8 °C (Fig. 3c). Next, we studied three mutants, all in the L26P background, designed to decrease helicity of the polyQ tract (L56P), Tau-1 (A186P, L192P and C238P) or Tau-5 (A356P, A398P and T435P). We observed that these alterations increased the  $T_c$  to varying degrees: L56P increased it by 5 °C, as did substitutions in Tau-1, but those in Tau-5 had a larger effect, of approximately 10 °C. (Fig. 3b,c). We also analyzed the effect of TFE on phase separation propensity: it increased the helical propensity of the most helical motifs in Tau-1 and Tau-5 (Fig. 3a) and decreased the  $T_c$  of the AD, by 12 °C at 2.5% TFE (vol/vol) and by 35 °C at 5% TFE (Fig. 3c), suggesting that regions with helical propensity enhance AR AD phase separation in vitro<sup>44</sup>.

We examined the effect of reduced AR AD helicity on phase separation in cells. For this purpose, we developed an assay to stabilize the cytosolic AR condensates by deleting the native NLS (<sup>629</sup>RKLKK<sup>633</sup>) to obtain eGFP-AR- $\Delta$ NLS (Extended Data Fig. 4a). DHT stimulation of PC3 prostate cancer cells expressing this variant led to the formation of large cytosolic AR condensates, which can facilitate the use of live-cell imaging to examine how substitutions affect the size of the condensates because the lack of interactions with chromatin does not limit their growth (Extended Data Fig. 4b,c). The condensates were spherical; their number hardly changed over time, but their size increased substantially (Extended Data Fig. 4d). In addition, the condensates fused (Extended Data Fig. 4e) and recovered fluorescence intensity quickly after photobleaching (mobile fraction = 94 ± 8%, and half-time of recovery ( $t_{1/2}$ ) = 2.29 ± 1.17 s) both 1 h and 24 h after DHT stimulation (Extended Data Fig. 4f). Helix-breaking substitutions in Tau-1 had a negligible effect on the formation and dynamics of cytosolic

AR condensates, but substitutions in Tau-5 decreased the number and size of condensates following short-term (5–15 min) hormone exposure (Fig. 3b,d,e and Extended Data Fig. 4g). This indicates that regions with helical propensity in the Tau-5 subdomain enhance AR phase separation in cells<sup>45</sup>.


Our results show that aromatic residues drive AR phase separation but do not explain why hormone binding triggers it (Fig. 2a). Androgen binding to the LBD causes a conformational change that leads to AR oligomerization due to the formation of two dimerization interfaces: the N/C interaction<sup>29</sup> and the homotypic dimerization of the AR LBD<sup>46</sup>. These dimerization processes do not change the strength of the interactions between aromatic residues, but each doubles the valency of the freely diffusing AR species. According to theory<sup>47</sup>, coarse-grained simulations<sup>48</sup> and experiments<sup>49</sup>, this decreases the minimal concentration needed for phase separation. In agreement with this hypothesis, eGFP-AR- $\Delta$ NLS lacking the<sup>23</sup>FQNL<sup>27</sup> motif ( $\Delta$ FQNLF) formed fewer and smaller condensates in PC3 cells (Extended Data Fig. 4h–j). Similarly, when we incubated the AD in vitro with 1 molar equivalent of hormone-bound LBD, at a concentration (20  $\mu$ M) and solution conditions (25 °C, 200 mM NaCl) that do not lead to its phase separation, we observed the formation of droplets containing both domains (Fig. 3f,g); by contrast, AD lacking the<sup>23</sup>FQNL<sup>27</sup> motif formed smaller condensates (Fig. 3f,g). We conclude, therefore, that AR oligomerization upon activation leads to its phase separation (Fig. 3h).

### Rational design of small molecules with enhanced potency

EPI-001 is a small-molecule inhibitor of the AR AD, identified by phenotypic screening, that was investigated in clinical trials but was insufficiently potent<sup>24,50</sup>. Solution NMR and molecular simulations have shown that the compound forms a dynamic complex with a collapsed, partially helical state of Tau-5 that is stabilized in part by interactions between the aromatic rings of EPI-001 and the side chains of aromatic residues<sup>23,51</sup>. Because the condensates are stabilized by interactions between aromatic residues (Fig. 1) and the conformation adopted by the AR AD in this complex is related to that leading to condensation (Fig. 3), we hypothesized that EPI-001 partitions within the condensates formed by the AR AD and that this contributes to its mechanism of action. To investigate this, we measured, using high-performance liquid chromatography (HPLC), the equilibrium concentrations of EPI-001 in a biphasic system (Fig. 4a) and found that it indeed partitions within the AR AD liquid phase, with a high partition coefficient ( $P^{WT}_{EPI-001} = [EPI-001]_{dense} / [EPI-001]_{light} \approx 55$ ). We also studied its partitioning in the condensates formed by the 8YtoS mutant and obtained an approximately 40% lower partition coefficient ( $P^{8YtoS}_{EPI-001} \approx 32$ ), indicating that the aromatic character of the AR AD liquid phase is a determinant of partitioning.

We hypothesized that optimizing the distance and orientation of aromatic rings, and modulating the flexibility of the functional group connecting them, would facilitate the interaction of this molecule with the aromatic side chains of the target and increase its potency. We synthesized a series of compounds in which the carbon atom between the aromatic rings of EPI-002, the (2R,19S) stereoisomer of EPI-001, was replaced by two carbon atoms separated by a single (compound 4aa), a double (2aa, *cis* and 3aa, *trans*) or a triple (1aa) bond (Fig. 4b,c). The potency of the compounds was evaluated in LNCaP cells transfected with a luciferase reporter driven by an AR-dependent promoter and enhancer<sup>24,50,52</sup>. Compounds 2aa and, in particular, 1aa were the most potent inhibitors, and were substantially more potent than EPI-002 (Fig. 4b and Extended Data Fig. 5a).

To confirm that this led to an optimized interaction with the AR AD, we analyzed the NMR spectrum of Tau-5\* in the presence of the compounds. The chemical-shift perturbations caused by 1 molar equivalent of 1aa were larger than those induced by EPI-001, indicating that the interaction's strength was enhanced (Fig. 4d and Extended Data Fig. 5b). We also simulated the interaction of the compounds with residues 391




**Fig. 3 | Short transient helices enhance AR phase separation.** **a**, Annotation of short helical motifs in the AR AD. The plots show the helical propensity of the WT\* AD, measured by NMR in the absence or presence of 2.5% or 5% TFE. Tau-1 and Tau-5 are highlighted. A discontinuous contour indicates motifs that fold when bound to globular binding partners. Helicity values were derived from the main-chain chemical shifts by using 62D (ref. 67). Green values are from an equivalent experiment carried out with the Tau-5\* construct (ref. 23), which was done because the most informative resonances are invisible in AR AD owing to their involvement in transient long-range interactions. **b**, The mutants that were used to investigate the effect of reduced helical propensity on phase separation. The color code is the same as that in **a**. **c**,  $T_c$  measurements of purified AR AD proteins containing proline substitutions (mean  $\pm$  s.d.,  $n = 3$  independent samples), or in the presence of TFE. The solid shading represents the one-phase regime, and droplets represent the two-phase regime. **d**, Representative ( $n > 3$ ) live-cell fluorescence microscopy images of DHT-treated PC3 cells expressing

the indicated eGFP-AR- $\Delta$ NLS mutants. Scale bar, 10  $\mu$ m. **e**, Distributions of droplet size for eGFP-AR- $\Delta$ NLS and mutants in PC3 cells as a function of  $t_{DHT}$ . Each dot corresponds to the mean droplet size in a single cell ( $n > 20$  cells), boxes show the mean and the quartiles of all cells and  $P$  values were calculated using a Mann–Whitney  $U$  test. n.s., not significant. **f**, Representative ( $n > 3$ ) fluorescence microscopy images of purified AR AD (WT and  $\Delta$ FQNLF), the LBD and an equimolar mixture of the two proteins in vitro. In the images, the red (AR AD) and green (LBD) channels are merged; 200 mM NaCl and 20  $\mu$ M protein were used. Approximately 1% of the total amount of protein is labeled. Scale bars, 5  $\mu$ m. **g**, Distributions of the size of droplets ( $n = 750$  droplets for WT and  $n = 150$  for  $\Delta$ FQNLF) from the samples in **f**, where boxes show the mean and quartiles of all droplets, and average density of droplets in the cells ( $n = 4$  independent samples). **h**, Scheme illustrating how the N/C interaction and LBD homodimerization each double the valency ( $N$ ) of the freely diffusing AR species, thus increasing AR phase separation propensity.

to 446 of the AR AD<sup>51</sup> (Fig. 4e) and observed that its atoms contacted those of Iaa more frequently than those of EPI-002, leading to a more stable and structured complex. The simulated dissociation constant ( $K_D$ ) was  $1.4 \pm 0.1$  mM for Iaa versus  $5.2 \pm 0.4$  mM for EPI-002, in agreement with the NMR and gene reporter data (Fig. 4f and Extended Data Fig. 5c,d). Given that the droplets formed by the AR AD are stabilized by hydrophobic and aromatic interactions (Fig. 1), we synthesized analogs of Iaa with substitutions in positions  $R_1$  and  $R_2$  (Fig. 4g,h and Extended Data Fig. 5e) to modulate the hydrophobic and aromatic

character of the compounds. Introduction of a methyl ( $\text{CH}_3$ ) group at  $R_1$  (achieved with compound 1ba) or  $R_2$  (compound 1ab) increased the potency, reflected by the half-maximal inhibitory concentration ( $\text{IC}_{50}$ ) changing from approximately 5  $\mu$ M to approximately 1  $\mu$ M; after introduction of this group in both positions (compound 1bb), the  $\text{IC}_{50}$  was 0.5  $\mu$ M in the luciferase reporter system. In line with this, the introduction of a tert-butyl ( $\text{C}(\text{CH}_3)_3$ ) group at  $R_2$ , bearing three methyl groups (compound 1af), led to an  $\text{IC}_{50}$  of approximately 0.22  $\mu$ M. Substitution of hydrogen by fluorine (compound 1ad) or a methoxy ( $\text{CH}_3\text{O}$ ) group




**Fig. 4 | Optimization of the structure of EPI-001.** **a**, Experimental set-up for the measurement of the partition coefficient of EPI-001 in condensed ARAD. LLPS, liquid–liquid phase separation. **b,c**, Chemical structures of EPI-002 and compounds, with a modified linker between the two aromatic rings of EPI-002. **b**, Schematic of the structures and the corresponding  $IC_{50}$  measured in androgen-induced PSA-luciferase assay. Purple and brown circles correspond to chemical groups depicted in **c**, in which hydrogens are at the  $R_1$  and  $R_2$  positions. **d**, Changes in  $^{15}N$  chemical shift ( $\delta N$ ) in the NMR spectra of Tau-5\* ( $60 \mu M$ ) as a function of amino acid positions, caused by addition of 1 molar equivalent of EPI-001 (blue) or 1aa (red). Orange circles indicate aromatic amino acids in the sequence of Tau-5\*. RI-3 (ref. 23) and polyP regions are highlighted in light and dark gray, respectively. Samples contained 200 mM NaCl and 2% DMSO- $d_6$ . **e**, Illustrated molecular dynamics (MD) snapshot of the AR AD interacting with 1aa. Helices are shown in dark and light blue; the loop between them is gray. 1aa is shown in green, and chlorine is purple. **f**, Per-residue

contact probabilities observed in REST2 MD simulations between Tau-5 residues 391–446 and the compounds EPI-002 (blue) or 1aa (red). Contacts are defined as occurring in frames in which any non-hydrogen ligand atom is within 6.0 Å of a non-hydrogen protein atom. Orange circles represent the positions of aromatic residues. Values are presented as mean  $\pm$  statistical errors from block averaging. **g**, Compounds developed from 1aa, and their corresponding potency in the androgen-induced PSA-luciferase assay. **h**, Correlation between the activity of the compounds in the PSA-luciferase assay and their hydrophobicity in terms of LogD determined by chromatography (ChromLogD). **i**, Dose-dependent inhibition of AR-V7 transcriptional activity by 1ae. **j,k**, Effect of 1 molar equivalent EPI-001 and 1ae on the  $T_c$  of AR AD (average  $\pm$  s.d.,  $n = 3$  independent samples) (**j**) and on the distribution of droplet sizes ( $n > 4,000$  droplets for DMSO,  $n > 2,500$  for EPI-001 and  $n > 2,000$  for 1ae), where boxes show the mean and the quartiles of all droplets (**k**).

(compound 1ac) at position  $R_2$  barely changed the  $IC_{50}$ , but introduction of an additional aromatic ring (compound 1ae) at this position led to an  $IC_{50}$  of approximately 1.5  $\mu M$  (Fig. 4g,h).

Next, we measured the inhibitory potential of the compounds using the V7BS3-luciferase reporter, designed specifically for AR-V7

(ref. 53). As expected, 5  $\mu M$  enzalutamide, which binds to the AR LBD, had no activity against AR-V7-induced V7BS3-luciferase activity, whereas 35  $\mu M$  EPI-002 blocked luciferase activity, consistent with previous reports<sup>52</sup> (Extended Data Fig. 5f). Notably, 1ae was the most potent inhibitor of AR-V7 transcriptional activity, in a dose-dependent



**Fig. 5** | **1ae** decreases interactions between AR and the transcription machinery. **a**, Schematic of the method for small-molecule treatment of cells and the BioID experiment. **b**, BioID–MS of LNCaP MTID-AR-WT cells treated with EPI-001 (10  $\mu$ M, 1 h), followed by treatment with DHT and biotin (2 h). Intensity data were obtained from SAINTq analysis. Shown is the  $\log_2(\text{FC})$  of the intensity of the interaction in inhibitor-treated versus DMSO-treated cells. Decreased interactors in inhibitor-treated cells relative to DMSO-treated cells are shown in blue;  $P < 0.05$ . The dashed lines mark where  $\log_2(\text{FC}) < -1.5$ . Increased interactors in inhibitor-treated cells relative to DMSO-treated cells are shown in red;  $P < 0.05$ . The dashed lines mark where  $\log_2(\text{FC}) > 1.5$ . Proteins of interest are annotated ( $n = 3$ ). **c**, As in **b**, BioID–MS of LNCaP MTID-AR-WT cells. Cells were treated for 1 h with 1ae (5  $\mu$ M) and then for 2 h with DHT and biotin ( $n = 3$ ). **d**, (Total mean) TMean intensities of peptides identified by MS ( $n = 3$ ) from SAINTq data of individual proteins (bait), total interactors (all) or collated known AR interactors sourced from BioGrid (<https://thebiogrid.org/>) were compared between LNCaP MTID-AR-WT cells treated with DMSO and those treated with


small-molecule inhibitors. **e**, GO search terms of key biological processes and molecular functions in SAINTq intensity data from **b** and **c** (BFDR  $< 0.02$ , depleted =  $\log_2(\text{FC}) < -1.5$ ), obtained from the LNCaP MTID-AR-WT cells treated with small-molecule inhibitors versus DMSO. Full categories are available in Supplementary Data Table 2. **f**, BioID–MS of the LNCaP MTID-AR-WT interaction with Mediator complex in cells treated with small-molecule inhibitors versus DMSO. SAINTq data, color indicates strength of interaction change from  $\log_{\text{FC}_{10}}$  TMean of intensity. **g**, The TMean intensity of interactions with the MED1 subunit of Mediator was compared between LNCaP MTID-AR-WT cells treated with DMSO or small-molecule inhibitors. SAINTq data were used. Statistical significance was determined by Student's *t*-test against the control group. **h**, Results from a PLA in LNCaP MTID-AR-WT cells, using the indicated antibodies shown in cyan with DAPI staining shown in magenta. Cells were treated with small-molecule inhibitors or DMSO and DHT at the indicated times. Scale bars, 10  $\mu$ m. **i**, Distributions of PLA foci per cell, each dot corresponds to a cell and boxes shown the mean and quartiles of all cells ( $n > 20$  cells).

manner (Fig. 4i) ( $\text{IC}_{50} = 4.1 \mu\text{M}$ ), whereas 1ab and 1bb had no inhibitory effects (Extended Data Fig. 5g,h). In line with these results, 1ae blocked the proliferation of both LNCaP and LNCaP95 cells, driven by full-length AR and AR-V7, respectively (Extended Data Fig. 5i), whereas enzalutamide blocked the proliferation of only LNCaP cells, consistent with its mechanism of action (Extended Data Fig. 5j). In addition, to confirm that partitioning in the ARAD condensates contributes to the mechanism of this optimized ARAD inhibitor, we compared the extent to which EPI-001 and 1ae decrease the  $T_c$  of the ARAD and increase the

size of the droplets that it forms. In agreement with polyphasic linkage<sup>54,55</sup>, we found that EPI-001 decreases the  $T_c$  and increases the size of the droplets, and that, at the same concentration, 1ae has a larger effect (Fig. 4j,k).

To understand the mechanisms by which the inhibitors decrease AR transcriptional activity, we performed a BioID–MS analysis in LNCaP cells stably expressing MTID-AR-WT that were treated with EPI-001 or 1ae (Fig. 5a and Extended Data Fig. 6a) and found that both inhibitors caused a general decrease in AR interactions (Fig. 5b,c). 1ae caused a





**Fig. 6 | Compound 1ae inhibits AR-dependent transcription and tumor growth.** **a**, Structure of 1ae, and a schematic of the experiment used to investigate its effect on LNCaP cells. **b**, Representative ( $n > 3$ ) images of LNCaP cells (stained with Hoechst) after 96 h of treatment. Scale bar, 50  $\mu$ m. **c**, Dose-response curve (log-logistic fit) of viable LNCaP nuclei, with  $IC_{50}$  values calculated from the dose-response curve ( $n = 6$ ). **d**, Volcano plots of differentially expressed genes in LNCaP cells treated with EPI-001 or 1ae for 24 h at a concentration near the  $IC_{50}$  versus cells treated with DMSO (fold change cutoffs: 2 $\times$ , 0.5 $\times$ ). (Supplementary Data Table 3). **e**, Gene set enrichment analysis of the top 10 enriched and top 10 depleted msigdb hallmark signature pathways<sup>68</sup> in LNCaP cells treated with EPI-001 or 1ae versus those treated with DMSO. Circle size represents the significance of the normalized enrichment score ( $\log(P_{adj})$ ), and the color gradient represents normalized enrichment score of the indicated pathway analyzed with GSEA. The hallmark androgen-response pathway is highlighted in gray ( $n = 3$ ). **f**, The log transformation of mean normalized counts of the indicated gene sets in LNCaP

cells treated with EPI-001 or 1ae. Light lines represent individual genes, dark lines represent average of all genes and the shaded areas represent the standard error ( $n = 3$ ). **g**, Representative ( $n = 3$ ) western blot of endogenous AR in LNCaP cells pretreated with cycloheximide (CHX) for 3 h, which were then treated with 1ae for 21 h. GAPDH was used as the loading control (bottom). **h**, Schematic of the LNCaP and LNCaP95-D3 xenografting procedure in the CRPC model. **i**, Tumor volume in mice with LNCaP (left) or LNCaP95-D3 (right) xenografts. Values are presented as the mean percentage relative to the volume measured at the first day of treatment with the error bars representing the s.e.m. of  $n \geq 8$  (LNCaP) or  $n \geq 7$  (LNCaP95-D3) tumors per treatment group. Enza., enzalutamide. **j**, Tumor volume on day 28 or 20 of the experiments, presented as the percentage relative to the volume measured at the first day of treatment. **k**, Body weight of animals on day 28 or 20 of the xenograft experiments, presented as percentages relative to the body weight measurement on the first day of treatment. Horizontal bars in **j** and **k** represent the median.

stronger decrease in interactions than EPI-001; in addition, it exhibited a significant decrease in interactions with known AR interactors in the BioGrid database (Fig. 5d). An enrichment analysis of the depleted interactors revealed that the decrease was more marked for 1ae in

all categories, in line with its higher potency (Fig. 5e and Supplementary Data Table 2). Focusing on Mediator, we found that, among all its subunits, MED1 was the most significantly reduced by 1ae (Fig. 5f,g and Extended Data Fig. 6b,c). Finally, we used PLAs between AR and MED1

or ARID1A to validate these findings and found that, for both inhibitors, the total number of foci per cell was reduced as time of incubation increased (Fig. 5h,i). These data show that the small-molecule inhibitors decrease the extent to which AR interacts with the transcription machinery, thus inhibiting its transcriptional activity.

### Iae inhibits AR-dependent transcription and tumor growth

To further explore the potency and specificity of Iae and EPI-001 on the AR-driven transcriptional program, we used RNA sequencing (RNA-seq) on LNCaP prostate adenocarcinoma cells after treatment with approximately  $IC_{10}$  and  $IC_{50}$  doses of the compounds for 6 or 24 h (Fig. 6a–c and Extended Data Fig. 7a,b). Six-hour treatment with  $IC_{10}$  concentrations had negligible effects on the gene expression profile of prostate cancer cells (Extended Data Fig. 7a,b); by contrast, 24-h treatment with 25  $\mu$ M EPI-001 led to the differential expression of 64 genes, and 24-h treatment with 5  $\mu$ M Iae led to the differential expression of 231 genes, compared with DMSO-treated control cells (Fig. 6d). Gene set enrichment analysis (GSEA) revealed that downregulated genes were significantly enriched for known AR targets, for both EPI-001 and Iae ( $P_{adj} < 0.01$ ) (Extended Data Fig. 7c–e). Both EPI-001 and Iae dysregulated the same subset (5/50) of pathways tested with GSEA (Fig. 6e,f and Extended Data Fig. 7e). The significantly dysregulated pathways included the AR response pathway and other pathways that are known to be active in CRPC<sup>56,57</sup>. Of note, treatment with 5  $\mu$ M Iae, a concentration that does not alter AR levels (Fig. 6g and Extended Data Fig. 7f), led to a more profound reduction in the expression of all downregulated and differentially expressed genes that were induced than did treatment with 25  $\mu$ M of EPI-001 (Fig. 6f and Extended Data Fig. 7d). These results indicate that Iae inhibits AR-dependent targets in prostate cancer cells and is more potent in its transcriptional inhibitory effect than EPI-001.

The in vivo efficacy of Iae was tested on human CRPC xenografts in castrated mice. For this purpose, LNCaP cells (driven by the full-length AR), and LNCaP95-D3 cells (expressing elevated levels of the AR-V7 splice variant)<sup>58</sup> were xenografted into the mice. Iae was administered at a daily dose of 30 mg per kg body weight for 28 d (Fig. 6h). After 20–28 d of treatment, Iae modestly but significantly reduced tumor volumes in both the LNCaP and LNCaP95-D3 xenograft models compared with control animals (Fig. 6i,j): in the AR-V7-driven LNCaP95-D3 xenograft model of CRPC, Iae outperformed enzalutamide, a second-generation antiandrogen that targets the ARLBD. No overt toxicity was observed for Iae, as determined by the fact that there were no substantial differences in body weights among the animals at the end of the experiment (Fig. 6k). Finally, we confirmed the in vivo on-target activity of Iae for both AR-FL and AR-V7 in LNCaP and LNCaP95-D3 xenografts by analyzing gene expression in the tumors. Both enzalutamide and Iae inhibited androgen-induced genes in LNCaP xenografts, but only Iae was able to block AR-V7-mediated gene transcription in LNCaP95-D3 xenografts and, notably, it de-repressed the *B4GALT* gene, which is repressed by AR-V7 (ref. 59). In both models, neither enzalutamide nor Iae had an effect on the housekeeping gene *ALAS1* (Extended Data Fig. 8). In summary, although the activity of Iae on the LNCaP95-D3 xenograft is modest, its superiority to enzalutamide indicates that our approach leads to an inhibition of the ARAD.

### Discussion

Our data provide insights into the molecular basis of phase separation encoded in the AR, which may also apply to other transcriptional regulators. The cytosolic and nuclear condensates that AR forms are stabilized by interactions between aromatic residues, similar to condensates formed by various prion-like proteins<sup>28,60</sup>. In the ARAD, these cluster in the <sup>23</sup>FQNLF<sup>27</sup> motif and in the C terminus of the domain, which includes a sequence region that is key for transactivation in the absence of androgens<sup>61</sup> (Tau-5, Fig. 1c). The N/C interaction, stimulated by hormone binding, also contributes to stabilizing the condensates

by increasing the valency of AR<sup>29,46,62</sup>. The presence of partially folded helices in the ARAD further facilitates phase separation, especially in regions of sequence that are rich in aromatic residues, likely by projecting forward aromatic side chains.

Our results reveal unexpected links between phase separation and the functions of transcriptional regulators. We found that reducing phase separation of the ARAD inhibited transcriptional activity, consistent with previous studies on a small number of TFs<sup>15,20–22</sup> as well as nuclear translocation (Fig. 2a,b,e,f). We speculate that aromatic residues in the ARAD, which drive its phase separation, can interact with aromatic residues in FG repeats of nucleoporins, without the mediation of nuclear import receptors and adapter proteins<sup>63</sup>, to facilitate translocation. This idea is supported by the observation that substituting surface residues with aromatic ones in a large globular protein enhances translocation<sup>64</sup>. We conclude that AR activation by androgens leads to the formation of condensates that are stabilized by interactions between aromatic residues that are key for the receptor to perform its cytosolic and nuclear functions.

The molecular features driving AR phase separation suggest how the compounds that inhibit the ARAD function. We found that they partition into AR condensates in vitro, and that their partitioning into AR condensates is driven by interactions with aromatic residues in the ARAD (Fig. 4a). NMR experiments and molecular simulations revealed that the helical regions of sequence within Tau-5 form a transient binding pocket that facilitates the interaction (Fig. 4e,f). Stabilization of the pocket and covalent modification of the cysteine residues found in the ARAD trap it in a conformation that disfavors interactions with effector partners. This explains why the compounds reduce the  $T_c$  in vitro (Fig. 4j,k) and inhibit AR-co-activator interactions and AR-dependent transcription in cells (Figs. 5a–e and 6c–f). It also suggests that enhancing compound partitioning by optimizing hydrophobicity and aromaticity leads to increased potency of the compounds, consistent with the RNA-seq and viability data (Fig. 6a–f). We propose that other intrinsically disordered proteins contain sequences that assume transient secondary structures in condensates, and that such structures provide transient ‘druggability’ to the target protein, a proposal that is consistent with the evidence for the structure–activity relationship of the ARAD-targeting compounds described here (Fig. 4).

Finally, we show that targeting small molecules to the condensates formed by AR and, specifically, to the region of sequence that drives its phase separation has an antitumorigenic effect, specific to AR-dependent tumor growth, in an in vivo CRPC model driven by an ‘undruggable’ AR variant. Anti-androgens used as first-line therapy against prostate cancer, such as enzalutamide, target the LBD and inhibit activation by androgens<sup>65</sup>. A hallmark of CRPC is the emergence of AR splice variants that lack the LBD and are resistant to this class of drugs. Such isoforms consist of the DNA-binding domain and the disordered AD of the receptor, suggesting that its inhibition could inhibit prostate cell proliferation in CRPC. We took advantage of a previously described small molecule, EPI-001, clarified its mode of action, and improved its potency by using insights into the driving forces of AR phase separation and the physicochemical properties of the condensates that it forms. Our approach, based on the rational optimization of a drug-like small molecule initially identified by phenotypic screening<sup>24,50</sup>, is complementary to alternative strategies based on the identification of inhibitors of AR condensation<sup>19</sup> and on targeting Cys residues of the ARAD by the addition of electrophilic warheads to existing ligands<sup>66</sup>. In summary we establish a basis on which anti-CRPC drugs can be further developed, and we propose a generalizable framework for targeting with therapeutic intent the phase-separation capacity of intrinsically disordered regions in oncogenic transcription factors<sup>6</sup>.

### Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information,

acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41594-023-01159-5>.

## References

- Darnell, J. E. Jr. Transcription factors as targets for cancer therapy. *Nat. Rev. Cancer* **2**, 740–749 (2002).
- Bradner, J. E., Hnisz, D. & Young, R. A. Transcriptional addiction in cancer. *Cell* **168**, 629–643 (2017).
- Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature* **505**, 495–501 (2014).
- Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* **144**, 646–674 (2011).
- Bushweller, J. H. Targeting transcription factors in cancer—from undruggable to reality. *Nat. Rev. Cancer* **19**, 611–624 (2019).
- Biesaga, M., Frigolé-Vivas, M. & Salvatella, X. Intrinsically disordered proteins and biomolecular condensates as drug targets. *Curr. Opin. Chem. Biol.* **62**, 90–100 (2021).
- Huang, P., Chandra, V. & Rastinejad, F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. *Annu. Rev. Physiol.* **72**, 247–272 (2010).
- Heinlein, C. A. & Chang, C. Androgen receptor in prostate cancer. *Endocr. Rev.* **25**, 276–308 (2004).
- Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L. & Tindall, D. J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. *Cancer Res.* **68**, 5469–5477 (2008).
- Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. *Cancer Res.* **69**, 16–22 (2009).
- Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *N. Engl. J. Med.* **371**, 1028–1038 (2014).
- Scher, H. I. et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. *JAMA Oncol.* **2**, 1441–1449 (2016).
- Banani, S. F., Lee, H. O., Hyman, A. A. & Rosen, M. K. Biomolecular condensates: organizers of cellular biochemistry. *Nat. Rev. Mol. Cell Biol.* **18**, 285–298 (2017).
- García-Cabau, C. & Salvatella, X. Regulation of biomolecular condensate dynamics by signaling. *Curr. Opin. Cell Biol.* **69**, 111–119 (2021).
- Boija, A. et al. Transcription factors activate genes through the phase-separation capacity of their activation domains. *Cell* **175**, 1842–1855 (2018).
- Chong, S. et al. Imaging dynamic and selective low-complexity domain interactions that control gene transcription. *Science* **361**, eaar2555 (2018).
- Zhang, F. et al. Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression. *Nucleic Acids Res.* **51**, 99–116 (2023).
- Roggero, C. M. et al. Poly-glutamine-dependent self-association as a potential mechanism for regulation of androgen receptor activity. *PLoS ONE* **17**, e0258876 (2022).
- Xie, J. et al. Targeting androgen receptor phase separation to overcome antiandrogen resistance. *Nat. Chem. Biol.* **18**, 1341–1350 (2022).
- Basu, S. et al. Unblending of transcriptional condensates in human repeat expansion disease. *Cell* **181**, 1062–1079 (2020).
- Zhang, H. et al. Reversible phase separation of HSF1 is required for an acute transcriptional response during heat shock. *Nat. Cell Biol.* **24**, 340–352 (2022).
- Wang, J. et al. Phase separation of OCT4 controls TAD reorganization to promote cell fate transitions. *Cell Stem Cell* **28**, 1868–1883 (2021).
- De Mol, E. et al. EPI-001, a compound active against castration-resistant prostate cancer, targets transactivation unit 5 of the androgen receptor. *ACS Chem. Biol.* **11**, 2499–2505 (2016).
- Andersen, R. J. et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. *Cancer Cell* **17**, 535–546 (2010).
- Tomura, A. et al. The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein. *J. Biol. Chem.* **276**, 28395–28401 (2001).
- Black, B. E. et al. Transient, ligand-dependent arrest of the androgen receptor in subnuclear foci alters phosphorylation and coactivator interactions. *Mol. Endocrinol.* **18**, 834–850 (2004).
- Dyson, H. J. & Wright, P. E. Unfolded proteins and protein folding studied by NMR. *Chem. Rev.* **104**, 3607–3622 (2004).
- Martin, E. W. et al. Valence and patterning of aromatic residues determine the phase behavior of prion-like domains. *Science* **367**, 694–699 (2020).
- He, B. et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. *Mol. Cell* **16**, 425–438 (2004).
- Eftekharzadeh, B. et al. Hsp70 and Hsp40 inhibit an inter-domain interaction necessary for transcriptional activity in the androgen receptor. *Nat. Commun.* **10**, 3562 (2019).
- Bouchard, J. J. et al. Cancer mutations of the tumor suppressor SPOP disrupt the formation of active, phase-separated compartments. *Mol. Cell* **72**, 19–36 (2018).
- Sabari, B. R. et al. Coactivator condensation at super-enhancers links phase separation and gene control. *Science* **361**, eaar3958 (2018).
- Boehning, M. et al. RNA polymerase II clustering through carboxy-terminal domain phase separation. *Nat. Struct. Mol. Biol.* **25**, 833–840 (2018).
- Zhou, Z. X., Sar, M., Simental, J. A., Lane, M. V. & Wilson, E. M. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. *J. Biol. Chem.* **269**, 13115–13123 (1994).
- Tuttle, L. M. et al. Gcn4–Mediator specificity is mediated by a large and dynamic fuzzy protein–protein complex. *Cell Rep.* **22**, 3251–3264 (2018).
- Warfield, L., Tuttle, L. M., Pacheco, D., Klevit, R. E. & Hahn, S. A sequence-specific transcription activator motif and powerful synthetic variants that bind Mediator using a fuzzy protein interface. *Proc. Natl Acad. Sci. USA* **111**, E3506–E3513 (2014).
- Radhakrishnan, I. et al. Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: a model for activator:coactivator interactions. *Cell* **91**, 741–752 (1997).
- Brzovic, P. S. et al. The acidic transcription activator Gcn4 binds the mediator subunit Gal11/Med15 using a simple protein interface forming a fuzzy complex. *Mol. Cell* **44**, 942–953 (2011).
- Eftekharzadeh, B. et al. Sequence context influences the structure and aggregation behavior of a PolyQ tract. *Biophys. J.* **110**, 2361–2366 (2016).
- Escobedo, A. et al. Side chain to main chain hydrogen bonds stabilize a polyglutamine helix in a transcription factor. *Nat. Commun.* **10**, 2034 (2019).
- Bielskuté, S. et al. Low amounts of heavy water increase the phase separation propensity of a fragment of the androgen receptor activation domain. *Protein Sci.* **30**, 1427–1437 (2021).
- De Mol, E. et al. Regulation of androgen receptor activity by transient interactions of its transactivation domain with general transcription regulators. *Structure* **26**, 145–152 (2018).
- Luo, P. & Baldwin, R. L. Mechanism of helix induction by trifluoroethanol: a framework for extrapolating the helix-forming properties of peptides from trifluoroethanol/water mixtures back to water. *Biochemistry* **36**, 8413–8421 (1997).

44. Conicella, A. E., Zerze, G. H., Mittal, J. & Fawzi, N. L. ALS mutations disrupt phase separation mediated by  $\alpha$ -helical structure in the TDP-43 low-complexity C-terminal domain. *Structure* **24**, 1537–1549 (2016).
45. Hallegger, M. et al. TDP-43 condensation properties specify its RNA-binding and regulatory repertoire. *Cell* **184**, 4680–4696 (2021).
46. Nadal, M. et al. Structure of the homodimeric androgen receptor ligand-binding domain. *Nat. Commun.* **8**, 14388 (2017).
47. Martin, E. W. & Mittag, T. Relationship of sequence and phase separation in protein low-complexity regions. *Biochemistry* **57**, 2478–2487 (2018).
48. Dignon, G. L., Zheng, W., Kim, Y. C., Best, R. B. & Mittal, J. Sequence determinants of protein phase behavior from a coarse-grained model. *PLoS Comput. Biol.* **14**, e1005941 (2018).
49. Shin, Y. et al. Spatiotemporal control of intracellular phase transitions using light-activated optoDroplets. *Cell* **168**, 159–171 (2017).
50. Myung, J.-K. et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. *J. Clin. Invest.* **123**, 2948–2960 (2013).
51. Zhu, J., Salvatella, X. & Robustelli, P. Small molecules targeting the disordered transactivation domain of the androgen receptor induce the formation of collapsed helical states. *Nat. Commun.* **13**, 6390 (2022).
52. Banuelos, C. A. et al. Ralaniten sensitizes enzalutamide-resistant prostate cancer to ionizing radiation in prostate cancer cells that express androgen receptor splice variants. *Cancers* **12**, 1991 (2020).
53. Xu, D. et al. Androgen receptor splice variants dimerize to transactivate target genes. *Cancer Res.* **75**, 3663–3671 (2015).
54. Wyman, J. & Gill, S. J. Ligand-linked phase changes in a biological system: applications to sickle cell hemoglobin. *Proc. Natl Acad. Sci. USA* **77**, 5239–5242 (1980).
55. Posey, A. E. et al. Profilin reduces aggregation and phase separation of huntingtin N-terminal fragments by preferentially binding to soluble monomers and oligomers. *J. Biol. Chem.* **293**, 3734–3746 (2018).
56. Takeda, D. Y. et al. A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. *Cell* **174**, 422–432 (2018).
57. Rasool, R. U. et al. CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation. *Cancer Discov.* **9**, 1538–1555 (2019).
58. Leung, J. K., Tam, T., Wang, J. & Sadar, M. D. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones. *Hum. Cell* **34**, 211–218 (2021).
59. Cato, L. et al. ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer. *Cancer Cell* **35**, 401–413 (2019).
60. Li, H.-R., Chiang, W.-C., Chou, P.-C., Wang, W.-J. & Huang, J.-R. TAR DNA-binding protein 43 (TDP-43) liquid–liquid phase separation is mediated by just a few aromatic residues. *J. Biol. Chem.* **293**, 6090–6098 (2018).
61. Dehm, S. M., Regan, K. M., Schmidt, L. J. & Tindall, D. J. Selective role of an NH<sub>2</sub>-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. *Cancer Res.* **67**, 10067–10077 (2007).
62. Li, P. et al. Phase transitions in the assembly of multivalent signalling proteins. *Nature* **483**, 336–340 (2012).
63. Milles, S. et al. Plasticity of an ultrafast interaction between nucleoporins and nuclear transport receptors. *Cell* **163**, 734–745 (2015).
64. Frey, S. et al. Surface properties determining passage rates of proteins through nuclear pores. *Cell* **174**, 202–217 (2018).
65. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science* **324**, 787–790 (2009).
66. Thiyagarajan, T. et al. Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer. *Proc. Natl Acad. Sci. USA* **120**, e2211832120 (2023).
67. Camilloni, C., De Simone, A., Vranken, W. F. & Vendruscolo, M. Determination of secondary structure populations in disordered states of proteins using nuclear magnetic resonance chemical shifts. *Biochemistry* **51**, 2224–2231 (2012).
68. Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst.* **1**, 417–425 (2015).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

<sup>1</sup>Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany. <sup>2</sup>Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain. <sup>3</sup>Genome Sciences, BC Cancer and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. <sup>4</sup>Dartmouth College, Department of Chemistry, Hanover, NH, USA. <sup>5</sup>Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany. <sup>6</sup>Nuage Therapeutics, Barcelona, Spain. <sup>7</sup>Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA. <sup>8</sup>Institut de Biotecnologia i Biomedicina and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. <sup>9</sup>Departament de Química Inorgànica i Orgànica, Universitat de Barcelona, Barcelona, Spain. <sup>10</sup>Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Berlin, Germany. <sup>11</sup>ICREA, Barcelona, Spain. <sup>12</sup>These authors contributed equally: Shaon Basu, Paula Martínez-Cristóbal. ✉ e-mail: [msadar@bcgsc.ca](mailto:msadar@bcgsc.ca); [antoni.riera@irbbarcelona.org](mailto:antoni.riera@irbbarcelona.org); [hnisz@molgen.mpg.de](mailto:hnisz@molgen.mpg.de); [xavier.salvatella@irbbarcelona.org](mailto:xavier.salvatella@irbbarcelona.org)

## Methods

### Materials availability

All unique reagents generated in this study are available with a materials transfer agreement.

### Experimental model and subject details

**Cell culture.** PC3 (ATCC; CRL-1435) and LNCaP clone FGC (ATCC; CRL-1740) cells were cultured in RPMI-1640 containing 4.5 g L<sup>-1</sup> glucose (Glutamax, Gibco) supplemented with either 10% (vol/vol) charcoal-stripped serum (CSS, Thermo Fisher Scientific A3382101) or 5% FBS (vol/vol), as specified below, and antibiotics. Induction of transcriptional activation by the AR in experiments using 5% FBS cultured LNCaP cells (Fig. 6a–f and Extended Data Figs. 1a,d and 7a–e) was verified using high-resolution microscopy and quantitative reverse transcription PCR (qRT-PCR). HEK293T cells (ATCC; CRL-3216) and AR-eGFP HeLa stable cells<sup>69</sup> (a gift from the M. Pennuto lab) were maintained in DMEM containing 4.5 g L<sup>-1</sup> glucose supplemented with 10% (vol/vol) charcoal-stripped FBS and antibiotics. LNCaP95 cells were obtained from S. R. Plymate (University of Washington) and cultured in phenol-red-free RPMI supplemented with 10% (vol/vol) charcoal-stripped FBS (Gibco) and antibiotics. Cells were cultured in a humidified atmosphere containing 5% CO<sub>2</sub> at 37 °C. Cell cultures tested negative for mycoplasma contamination.

**Human prostate cancer xenografts.** All animal experiments adhere to regulatory and ethical standards and were approved by the University of British Columbia Animal Care Committee (A18-0077). Before any surgery, metaCAM (1 mg per kg body weight, 0.05 ml per 10 g body weight) was administered subcutaneously. Isoflurane was used as an anesthetic. CO<sub>2</sub> was used to euthanize the animals. Six- to eight-week-old male mice (NOD-scid IL2Rgamma<sup>null</sup>) were maintained at the Animal Care Facility at the British Columbia Cancer Research Centre. Five million LNCaP cells were inoculated subcutaneously in a 1:1 volume of matrigel (Corning Discovery Labware). Tumors were measured daily using digital calipers, and the volume was calculated using the formula for ovoid volume: length × width × height × 0.5236. When xenograft volumes were approximately 100 mm<sup>3</sup>, the mice were castrated, and treatment dosing started one week later. Animals were dosed daily by oral gavage with 30 mg per kg body weight of 1αe, 10 mg per kg body weight enzalutamide, or vehicle (5% DMSO, 1.5% Tween-80, 1% CMC).

### Cloning of constructs

The primers and synthetic genes used in this work are listed in Supplementary Data Table 6.

**GFP-AR FL, V7, and ΔNLS cloning strategy.** For peGFPC1-AR-ΔNLS, the NLS sequence (RKLKK, corresponding to amino acids 629–633 of AR) of the eGFP-AR fusion protein<sup>70</sup> was removed from peGFP-C1-AR (Addgene no. 28235) using the Q5 site-directed mutagenesis kit and primer design tools (New England Biolabs). Any clones found to have expansion or shrinkage of either the polyQ or polyG site in the AR were corrected by replacing the 1510-base-pair (bp) KpnI-KpnI fragment with that of the WT AR sequence from peGFP-C1-AR.

For peGFPC1A-V7, the V7 variant of AR was generated from peGFP-C1-AR using the Q5 site-directed mutagenesis kit and primer design tools (New England Biolabs). Any clones that were found to contain expansion or shrinkage of either the polyQ or polyG site in the AR were corrected by replacing the 1510-bp KpnI-KpnI fragment with that of the WT AR sequence from peGFP-C1-AR.

For monomeric eGFP (mEGFP) constructs, mEGFP was subcloned into vectors containing human AR (Addgene no. 29235) and AR-V7 (Addgene no. 86856) using Gibson assembly to create mEGFP-AR-FL and mEGFP-AR-V7 (referred to as AD+DBD+NLS in Fig. 1b and Extended Data Fig. 2a,b) mammalian expression vectors. AR-V7 contains a 16-amino-acid (aa) constitutively active NLS containing an exon that

replaces the LBD exons in AR-FL<sup>71</sup>. The sequence downstream of the AR activation domain in AR-V7, containing the DBD and NLS, was subcloned into an mEGFP plasmid (Addgene no. 18696) using Gibson assembly to create the mEGFP-AR-V7-ΔAD (referred to as DBD+NLS in Fig. 1b and Extended Data Fig. 2a,b) expression vector.

**AR tyrosine mutagenesis strategy.** Production of YtoS mutants for mammalian expression. The sequences were optimized for expression in human cells, synthesized and cloned into the pUC57 plasmid (high-copy AmpR) by GenScript Biotech. To enable simple excision from pUC57 and insertion into plasmids derived from peGFPC1-AR, two HindIII sites were included as flanks on the fragments. After digestion using HindIII, the resulting 1,722-bp fragments were excised from TBE agarose gels, purified using the E.Z.N.A. MicroElute Gel Extraction Kit (Omega Biotech) and ligated into HindIII-cut, calf intestinal alkaline phosphatase (CIP)-treated and gel-purified peGFPC1-AR, peGFPC1-AR ΔNLS or peGFPC1A-V7 plasmids to produce the YtoS mutants.

**Production of YtoS mutants for bacterial expression.** pDEST17 plasmids for bacterial recombinant production of AR AD YtoS mutants were synthesized by Thermo Fisher Scientific with open reading frame (ORF) sequences flanked with attB1 and attB2 sequences.

**AR helix-breaking mutagenesis strategy.** pDONR221-AR-AD-WT. The DNA sequence corresponding to the 1,558-aa fragment of AR-AD was synthesized and encoded in a pDONR221 vector by Thermo Fisher Scientific (flanked with attB1 and attB2 sequences).

**pDEST17-AR-AD-WT.** pDONR221-AR-AD-WT was subcloned into a pDEST17 vector using the LP clonase reaction (Thermo Fisher Scientific).

**pDEST17-AR-AD-WT\*.** L26P was introduced into a WT AR sequence (pDONR221-AR-AD-WT) using a Quickchange protocol with Pfu Turbo polymerase (Agilent), and the resulting plasmid with the L26P substitution (pDONR221-AR-AD-WT\*) was subcloned into a pDEST17 vector using the LP clonase reaction (Thermo Fisher Scientific).

**pDEST17-AR-AD-L56P\*.** L56P was introduced into the pDONR221-AR-AD-WT\* (bearing L26P; described above) using a Quickchange protocol with Pfu Turbo polymerase (Agilent) to generate pDONR221-AR-AD-L56P\*. The resulting plasmid with the L26P and L56P substitutions (pDONR221-AR-AD-L56P\*) was subcloned into a pDEST17 vector using the LP clonase reaction (Thermo).

**pDEST17-AR-AD-Tau-1\*.** The A186P, L192P and C238P substitutions were introduced in a step-wise manner into pDONR221-AR-AD-WT\* (bearing L26P; described above) using a Quickchange protocol with Pfu Turbo polymerase (Agilent) to generate pDONR221-AR-AD-Tau-1\*. The resulting plasmid with the L26P, A186P, L192P and C238P substitutions (pDONR221-AR-AD-Tau-1\*) was subcloned into a pDEST17 vector using the LP clonase reaction (Thermo Fisher Scientific).

**pDEST17-AR-AD-Tau-5\*.** The A356P, A398P and T435P substitutions were introduced in a step-wise manner into pDONR221-AR-AD-WT\* (bearing L26P; described above) using a Quickchange protocol with Pfu Turbo polymerase (Agilent) to generate pDONR221-AR-AD-Tau-5\*. The resulting plasmid with the L26P, A356P, A398P and T435P substitutions (pDONR221-AR-AD-Tau-5\*) was subcloned into a pDEST17 vector using the LP clonase reaction (Thermo Fisher Scientific).

**pDEST17-AR-AD-L56P+Tau-1+Tau-5\*.** The L56P, A186P, L192P and C238P substitutions were introduced in a step-wise manner into pDONR221-AR-AD-TAU-5\* (bearing the L26P, A186P, L192P and C238P substitutions; described above) using a Quickchange protocol with Pfu Turbo polymerase (Agilent) to generate pDONR221-AR-AD-L5

6P+Tau-1+Tau-5\*. The resulting plasmid containing the L26P, L56P, A186P, L192P, C238P, A356P, A398P and T435P substitutions (pDONR221-AR-AD-L56P+Tau-1+Tau-5\*) was subcloned into a pDEST17 vector using the LP clonase reaction (Thermo Fisher Scientific).

**eGFP-AR-ΔNLS-Δ21–35.** A 507-bp fragment with deletion of residues 21–35 was amplified from pCMV5-FLAG-AR deltaFQNLF<sup>30</sup> using KOD polymerase (Merck Millipore) and the supplied buffer no. 2. The resulting fragment was purified using AmPure XT (Beckman) before InFusion (Takara Bio) into Sall and AflIII-cut and gel-purified peGFPC1-ARΔNLS plasmid.

**eGFP-AR-ΔNLS-Tau-1.** The A186P, L192P and C238P substitutions were introduced in a step-wise manner into the WT AR sequence encoded in pDONR221-AR-AD-WT using a Quickchange protocol with Pfu Turbo polymerase (Agilent). A 755-bp fragment was amplified from the resulting clone, incorporating the A186P, L192P and C238P substitutions (pDONR221-AR-AD-TAU1), using KOD polymerase (Takara Bio). The resulting fragment was digested with DpnI to remove the template and purified using AmPure XT (Beckman) before InFusion into AflIII-BstEII-cut and gel-purified peGFP-C1-ARΔNLS plasmid.

**eGFP-AR-ΔNLS-Tau-5.** The A356P, A398P and T435P substitutions were introduced in a step-wise manner into the WT AR sequence (pDONR221-AR-AD-WT) using a Quickchange protocol with Pfu Turbo polymerase (Agilent). A 1,544-bp fragment was then amplified from the resulting plasmid, incorporating the A356P, A398P and T435P substitutions (pDONR221-AR-AD-TAU-5), using KOD polymerase (Takara Bio). The resulting fragment was digested with DpnI to remove the template and purified using AmPure XT (Beckman) before InFusion into KpnI-cut and gel-purified peGFP-C1-ARΔNLS plasmid.

**BioID plasmid-generation strategy.** Constructs for expression of FLAG-MTID or its fusions with AR WT and 22YtoS were synthesized by Genscript and were either cloned into pcDNA3.1(–) and subsequently cloned into pLenti-CMV-MCS-GFP-SV-puro using XbaI and BamHI to replace GFP or cloned directly into pLenti-CMV-MCS-GFP-SV-puro by Genscript using the same sites. Sequences were codon optimized for mammalian expression and verified by sequencing. pLenti-CMV-MCS-GFP-SV-puro was a gift from P. Odgren (Addgene plasmid no. 73582).

## Experiments in vitro

**Expression and purification of constructs.** WT and mutant AR AD (1–558 aa) were recombinantly produced in *E. coli* Rosetta (DE3) cells that were transformed with pDEST17 plasmid encoding His-AR-AD, as described previously<sup>72</sup>. Briefly, cell cultures at an optical density of 600 nm (OD<sub>600</sub>) of 0.5 were induced with 0.1 mM IPTG at 22 °C overnight. Cells were lysed in PBS buffer and centrifuged. The pellet was solubilized overnight in Tris buffer (20 mM Tris, 500 mM NaCl, 5 mM Imidazole, pH 8) containing 8 M urea and 500 mM NaCl at pH 8. The protein was captured on Nickel columns (His Trap HP, GE Healthcare) and eluted with 500 mM imidazole. After urea removal by dialysis, the His-tag was cleaved by TEV protease at 4 °C overnight. Urea (8 M) was added to cleaved protein before reverse-nickel affinity chromatography to separate noncleaved protein and the His-tag. Protein in the flowthrough was concentrated, filtered and stored at –80 °C. To prevent protein aggregation or instability, an additional purification step was conducted, and the sample was run on a Superdex 200 16/600 column pre-equilibrated with AR AD buffer (20 mM sodium phosphate, 1 mM TCEP pH 7.4). Tau-5\* (330–448 aa) was expressed and purified as previously described<sup>43</sup>, and an equivalent protocol was used to express and purify fragment ARAD (441–558 aa).

AR-LBD (663–919 aa) containing an amino-terminal His-tag and encoded in a pET15b plasmid (Addgene no. 89083) was expressed in Rosetta (DE3) cells with 1 mM IPTG at 16 °C overnight. Cells were

resuspended in Ni-Wash buffer (25 mM HEPES, 500 mM NaCl, 10% glycerol, 1 mM DTT, 10 μM DHT, 1% Tween-20, 20 mM imidazole at pH 7.4), lysed and centrifuged. Soluble protein was captured by IMAC and eluted with 500 mM imidazole. During an overnight dialysis, His-tag was cleaved by thrombin (GE Healthcare), and the NaCl concentration was reduced to 100 mM. Cleaved protein was captured by cation exchange (GE Healthcare) and eluted with 1 M NaCl gradient. LBD was injected in a Superdex 200 16/600 column pre-equilibrated with 25 mM HEPES, 250 mM NaCl, 10% glycerol, 1 mM TCEP, 10 μM DHT, 1 mM EDTA and 0.5% Tween-20 at pH 7.2.

MED1 IDR (948–1573), encoded in a peTEC plasmid, was a gift from T. Graf. A 3C cleavage site was introduced by Q5 site-directed mutagenesis (New England Biolabs) between mCherry and the MED1 sequence, yielding peTEC-His-mcherry-3C-MED1-IDR plasmid. Protein was expressed in B834 (DE3) cells at 16 °C overnight with 0.1 mM IPTG. Upon cell lysis in Tris buffer with 100 mM NaCl, the soluble cell fraction was injected in a HisTrap HP column, and protein was eluted with 500 mM imidazole. The eluted protein was concentrated and separated by cation exchange chromatography. The collected fractions were cleaved by 3C protease, and MED1 IDR was separated from other protein fragments by size-exclusion chromatography (SEC) with Superdex 200 16/600 column pre-equilibrated with 20 mM sodium phosphate, 100 mM NaCl and 1 mM TCEP at pH 7.4.

RNAPII CTD (1592–1970) was produced in *E. coli* B834(DE3) cells transformed with the pDEST17 plasmid, which encodes H6-3C-RNAPII-CTD. The protein was expressed at 25 °C overnight with 0.1 mM IPTG and extracted from the insoluble cell fraction. The pellet was resuspended in Tris buffer with 8 M urea and loaded on a HisTrap HP column. Captured protein was dialyzed against 50 mM Tris-HCl, 50 mM NaCl and 1 M NaCl at pH 8 and was cleaved by 3C protease overnight at 4 °C. RNAPII CTD was injected in a Superdex 200 16/600 column pre-equilibrated with 20 mM sodium phosphate, 150 mM NaCl, 5% glycerol and 1 mM TCEP at pH 7.4.

AR-LBD, MED1-IDR and RNAPII-CTD fractions from SEC were concentrated, filtered and stored at –80 °C until further use.

**Turbidity measurements.** Protein samples were prepared in AR AD buffer (20 mM sodium phosphate, 1 mM TCEP pH 7.4), with the indicated protein and NaCl concentrations, on ice. Samples were centrifuged at 21,130 r.c.f. for 20 min at 4 °C, and the supernatant was transferred to a quartz cuvette. Phase separation  $T_c$  measurements of protein solutions were monitored by measuring the absorbance of the solutions at 340 nm as a function of temperature on a Cary 100 Multi-cell UV-vis spectrophotometer, equipped with a Peltier temperature controller, at a heating rate of 1 °C min<sup>–1</sup>. The  $T_c$  values were obtained as the maximum of the first-order derivative of the obtained curves from three independent samples.

**Protein labeling.** For in vitro condensation experiments, proteins were labeled with fluorescent dye instead of being tagged with fluorescent protein, to avoid nonspecific interactions in heterotypic condensates. AR AD and MED1 IDR were fluorescently labeled with Dylight 405 or Alexa Fluor 647, respectively, unless otherwise indicated in the figure legends. LBD and RNAPII-CTD were labeled with Oregon Green 488. In all cases, sulfhydryl-reactive dyes were used, which reacted to the naturally occurring cysteines of the protein, except for RNAPII-CTD in which an N-terminal Cys was added. Protein was labeled according to the manufacturer's instructions for sulfhydryl-reactive dyes (Thermo Fisher Scientific). Briefly, protein and dye were mixed at a 1:20 ratio in each protein storage buffer, adjusted to pH 7.5 overnight at 4 °C. Then, 1 mM DTT was added to stop the reaction, and protein was separated from free dye with a pre-equilibrated PD-10 column. Protein was concentrated and filtered, and the concentration and conjugation efficiency were analyzed, following the manufacturer's instructions for sulfhydryl-reactive dyes (Thermo Fisher Scientific).

**Fluorescence microscopy of in vitro protein condensation.** Each protein solution was prepared by adding approximately 1% of equivalent labeled protein. Solutions were stored on ice. Samples were prepared by mixing proteins at the indicated protein concentration with AR AD buffer (20 mM sodium phosphate, 1 mM TCEP pH 7.4) in low binding PCR tubes at RT. Once all proteins were mixed, the phase separation trigger was added: NaCl for AR samples, or Ficoll 70 for transcriptional component samples. Samples were homogenized, and 1.5  $\mu$ l of sample was transferred into sealed chambers composed of a slide and a PEGylated coverslip sandwiching 3M 300 LSE high-temperature double-sided tape (0.34 mm). Coverslips were PEGylated according to the published protocol<sup>73</sup>. Images were taken using Zeiss LSM 780 Confocal Microscope with a Plan-ApoChromat  $\times$ 63/1.4 Oil objective lens. Fluorescence recovery after photobleaching (FRAP) experiments were recorded using the same set-up on a 50  $\mu$ M AR AD sample containing approximately 1% of protein labeled with DyLight 488 dye (Thermo Fisher Scientific) with 500 mM NaCl. The data were analyzed using the EasyFRAP software<sup>74</sup> to extract the mobile fractions and recovery half-times.

**NMR experiments.** Assignment strategy. All NMR experiments were performed at 5 °C (278 K) on either a Bruker 800 MHz (DRX or Avance NEO) or a Bruker Avance III 600 MHz spectrometer, both equipped with TCI cryoprobes, and versions 3.2 and 4.0.8 of TOPSPIN.

A 300  $\mu$ M <sup>15</sup>N, <sup>13</sup>C-double-labeled AR AD (441–558 aa) sample in NMR buffer (20 mM sodium phosphate (pH 7.4), 1 mM TCEP, 0.05% (wt:vol) Na<sub>3</sub>) was used for backbone resonance assignment. The following series of three-dimensional (3D) triple resonance experiments were acquired: HNCO, HN(CA)CO, HNCA, HN(CO)CA, CBCANH and CBCA(CO)NH. Chemical shifts were deposited in the Biological Magnetic Resonance Bank (BMRB) (ID: 51476).

The assignment of AR AD (1–558 aa) was guided by the assignments obtained for the smaller AR fragments that were first studied here (residues 441–558) or previously reported (residues 1–151 (BMRB ID: 25607) and 142–448 (BMRB ID: 51479)). In addition, 3D HNCO and HNCA experiments were acquired for two <sup>15</sup>N, <sup>13</sup>C-double-labeled AR AD (1–558 aa) samples (25  $\mu$ M and 100  $\mu$ M) dissolved in NMR buffer. For the 100  $\mu$ M sample, additional 3D HN(CA)CO and HN(CO)CACB experiments were also recorded. Three-dimensional experiments were done using 25% non-uniform sampling. Chemical shifts were deposited in the BMRB (ID: 51480).

Backbone resonances of AR WT\* were almost identical to those of AR AD (1–558 aa), with only local differences in residues around the position substituted (L26), which were assigned using non-uniform sampled 3D BEST-TROSY HNCO and HNCA experiments<sup>75</sup> recorded on a 50  $\mu$ M <sup>15</sup>N, <sup>13</sup>C-double-labeled WT\* AR AD sample dissolved in NMR buffer.

**Site-specific and residue-type identification of oligomerization.** The oligomerization of AR AD was monitored by recording the induced intensity changes on the two-dimensional <sup>1</sup>H, <sup>15</sup>N correlation spectrum by adding increasing amounts of unlabeled sample on a 25  $\mu$ M <sup>15</sup>N-labeled AR AD to reach total concentrations of 57.5, 100.8, 122.5 or 155  $\mu$ M. Spectra were recorded using 128 scans per increment (with an experimental time of 21 h per spectrum) to ensure that intensities in the regions with weaker signals were quantified properly. Throughout the article, the term oligomer refers to intermolecular complexes formed through weak, and therefore reversible, site-specific interactions between monomers.

**Helicity studies upon TFE addition.** The effect of TFE on 50  $\mu$ M WT\* AR AD and Tau-5\* secondary structures were monitored by a series of <sup>1</sup>H, <sup>15</sup>N correlation spectra and non-uniform sampled 3D BEST-TROSY, HNCO and HNCA experiments recorded in the presence of increasing TFE amounts (0%, 2.5% and 5%).

**Binding studies.** EPI-001 and 1aa binding to Tau-5\* was studied by comparing <sup>15</sup>N chemical shifts in 2D <sup>1</sup>H, <sup>15</sup>N CP-HISQC<sup>76</sup> spectra at 37 °C (310 K), using 60  $\mu$ M Tau-5\* in the absence or presence of 60  $\mu$ M compounds (1:1 ratio). Samples contained NMR buffer (above) at pH 6.6 with 200 mM NaCl and 2% DMSO-d<sub>6</sub>. The CP-HISQC pulse sequence and the pH level of 6.6 were chosen to reduce water exchange of labile amide protons at 37 °C (310 K).

**Data processing.** Data processing was done using qMDD<sup>77</sup> for non-uniform sampled data, and NMRPipe<sup>78</sup> for all uniformly collected experiments. Data analysis was performed with CcpNmr Analysis<sup>79</sup>. Helix populations were extracted using the  $\delta$ 2D software<sup>87</sup>.

**Peptides.** FQNLFQ and FQNPFQ synthetic peptides were obtained as lyophilized powders with >95% purity from GenScript with amidated C and acetylated N termini. The lyophilized peptides were solubilized at a final concentration of 5 mM in DMSO. Immediately before each experiment, the stock solutions were diluted to 125  $\mu$ M in 20 mM HEPES buffer, pH 7.5, with 150 mM NaCl. For aggregation assays, the samples were incubated overnight at 37 °C at 600 r.p.m. agitation. The term aggregate refers to the quasi-irreversible formation of fibrillar species stabilized by strong intermolecular interactions, involving a large conformational change.

**Synchronous light scattering.** Synchronous light scattering was monitored using a JASCO Spectrofluorometer FP-8200. The conditions of the spectra acquisition were: excitation wavelength of 360 nm, emission range from 350 to 370 nm, slit widths of 5 nm, 0.5-nm interval and 1,000 nm min<sup>-1</sup> scan rate. The peptides were sonicated for 10 min in an ultrasonic bath (Fisher Scientific FB15052) before measurement.

**Fourier transform infrared spectroscopy.** Fourier transform infrared spectroscopy (FT-IR) experiments were performed using a Bruker Tensor 27 FT-IR spectrometer (Bruker Optics) with a Golden Gate MKII ATR accessory. Each spectrum consists of 16 independent scans, measured at a spectral resolution of 4 cm<sup>-1</sup> within the 1,800–1,500 cm<sup>-1</sup> range. All spectral data were acquired and normalized using the OPUS MIR Tensor 27 software. Data was afterwards deconvoluted using the Peak Fit 4.12 program. The buffer without peptide was used as a control and subtracted from the absorbance signal before deconvolution.

**Transmission electron microscopy.** The morphology of the aggregated FQNLFQ peptide was evaluated by negative staining using a JEOL JEM-1400Plus Transmission Electron Microscope. Five microliters of peptide solution was placed on carbon-coated copper grids and incubated for 5 min. The grids were then washed and stained with 5  $\mu$ l of 2% wt/vol uranyl acetate for 5 min. Then, the grids were washed again before analysis. Images and videos were processed with ImageJ.

## Cell imaging

**Microscopy.** PC3 cells were seeded in collagen-I-coated  $\mu$ -slide four-well glass-bottom plates (Ibidi 80426) at 60% confluency 24 h before transfection. Then, 170 ng of expression vectors encoding WT AR tagged with eGFP (eGFP-AR) or mutant AR proteins were transfected per well using polyethylenimine (PEI) (Polysciences) at a ratio of 1  $\mu$ g DNA to 3  $\mu$ l PEI. Four hours after transfection, the medium was changed to RPMI supplemented with 10% charcoal-stripped FBS and cells were cultured for 16 h before imaging. Transiently transfected PC3 cells expressing eGFP-AR were imaged in 3D during 1 min, by taking one image every 15 s, to acquire a baseline readout of AR expression. Cells were then treated immediately with 1 nM of DHT and imaged during 1 h, also by taking an image every 15 s. Time-lapse imaging was performed in an Andor Revolution Spinning Disk Confocal with an Olympus IX81 microscope and a Yokogawa CSU-XI scanner unit. Images were acquired with an Olympus PlanApo N  $\times$ 60/1.42 Oil objective lens. A

stable temperature (37 °C) was maintained during imaging under CO<sub>2</sub> in a temperature-regulated incubation chamber (EMBL). eGFP was excited with a 488 nm laser, and Z-stack images were acquired every 0.45 μm. Time-lapse images were compiled, processed and analyzed with Fiji (ImageJ)<sup>80</sup>. Intensity thresholds were set manually and uniformly to minimize background noise.

FLAG-MTID-AR-WT and PC3 FLAG-MTID-AR-WT-Y22toS cell lines were seeded in 24-well culture plates, on 12-mm sterilized coverslips. The next day, 50 μM biotin (or DMSO for a negative control) and 1 nM DHT were added for 2 h. The culture medium was removed and the cells were washed with PBS. Next, cells were fixed for 15 min with 4% paraformaldehyde. After fixation, cells were washed with PBS and then permeabilized with 0.1% Triton X-100 for 10 min. Coverslips were then washed and blocked with blocking buffer (3% BSA, 0.1% Tween, PBS) for 1 h at 37 °C. Coverslips were incubated with primary antibody—anti-AR (Abcam, ab108341, 1:100)—overnight. The next day, coverslips were washed with PBS, and secondary antibodies were added (1:500): anti-streptavidin antibody conjugated to Alexa Fluor 488 (Thermo Fisher Scientific, S11223) or Alexa Fluor 488-conjugated goat anti-rabbit-IgG (H+L) (Thermo Fisher Scientific, A11008). Fluorescence images were acquired using a Leica TCS SP8 confocal microscope. Images were taken with ×63 oil objectives, and standard LAS-AF software was used.

HEK293T cells in DMEM with 10% FBS were seeded at a density of 40,000 cells per well on glass-bottom chambered coverslips (Ibidi 80827). Sixteen hours later, wells were refreshed with 280 μl seeding medium and transfected with 50 ng of mEGFP expression plasmids, as shown in Extended Data Fig. 2a, using LipoD293 transfection reagent (SigmaGen SL100668) according to the manufacturer's protocol. Forty-eight hours later, wells were refreshed with medium spiked with 10 nM DHT or the equivalent DMSO control (vol/vol). Four hours after treatment, coverslips were imaged on a Zeiss LSM 880 confocal microscope with a Plan-ApoChromat ×63/1.4 Oil DIC objective lens in a CO<sub>2</sub> incubation chamber set to 37 °C. Images were acquired across two biological replicates.

**STED microscopy.** Sample preparation. HEK293T and HeLa eGFP-AR cells in DMEM with 10% FBS were seeded at a density of 40,000 cells per well on glass-bottom chambered coverslips (Ibidi 80827). Sixteen hours later, wells containing HEK293T cells were refreshed with 280 μl seeding medium and transfected with 50 ng of mEGFP expression plasmids, as shown in Fig. 1b, using LipoD293 transfection reagent (SigmaGen SL100668), according to the manufacturer's protocol. Forty-eight hours later, wells were refreshed with medium spiked with 10 nM DHT. Samples were imaged after 4 h of DHT treatment.

LNCaP cells (Clone FGC, ATCC CRL-1740) were seeded in RPMI-1640 5% FBS onto PLL-coated 18-mm no. 1.5 thickness glass coverslips (Sigma P4707, Roth LH23.1) at a density of 100,000 cells per coverslip on a 24-well plate. Sixteen hours later, the media was refreshed and cells were incubated further for another 24 h. For fixation, wells were washed with PBS, then fixed with 1 ml of 4% PFA in PBS for 20 min at room temperature. After a second wash in PBS, cells were permeabilized with 0.5% Triton X-100, PBS (vol/vol) (Sigma 93443) and then stained with anti-AR (AR 441, scbt 7305, 1:50) and STAR 635P secondary antibody (Abberior, ST635P-1001, 1:200). Nuclear translocation of the AR signal was validated by staining LNCaP cells grown in RPMI-1640 5% CSS (Gibco, A3382101), following the same protocol. DNA was counterstained with 1:2,000 Spy555-DNA (Spirochrome, SC201), and samples were mounted onto glass slides with vectashield (Biozol, VEC-H-1900-10).

**Live-cell STED.** HEK293T and HeLa cells were imaged on a Leica Stellaris STED DMI 8 microscope equipped with an okolab incubation chamber set to 37 °C and a constant concentration of CO<sub>2</sub> (5%). eGFP imaging was performed using a 473-nm stimulation wavelength laser at 20% power and a 592-nm depletion laser at 20% power. Images were taken

using a HC PL APO CS2 ×63/1.40 oil objective, with a final resolution of 23 nm pixel<sup>-1</sup>.

**Stimulated emission depletion fluorescence-lifetime imaging microscopy.** Fixed and stained LNCaP cells were imaged on a Leica Stellaris STED DMI 8 microscope. Abberior STAR 635P immunofluorescence imaging was performed using a laser with a stimulation wavelength of 633 nm at 5% power, and a 776-nm depletion laser at 5% power. Images were taken using a HC PL APO CS2 ×63/1.40 oil objective, with a final resolution of 48 nm pixel<sup>-1</sup>. Fluorescence-lifetime imaging microscopy cutoffs and fluorescence-lifetime stimulated emission depletion deconvolution strengths were determined automatically using Leica LAS-X software v2.5.6 to filter background photons with low fluorescence lifetimes (Extended Data Fig. 1d).

**FRAP assay in live cells.** PC3 cells were transfected and prepared for microscopy in identical conditions to those of the live-cell imaging experiments. Before performing FRAP assays, cells were treated with 1 nM DHT. FRAP data for each condition were acquired over the course of approximately 1 h after treatment, and results were combined for each condition because no trend was observed between FRAP data acquired at the beginning versus the end of the hour. FRAP measurements were performed on an Andor Revolution Spinning Disk Confocal microscope with a FRAPPA Photobleaching module and a iXon EMCCD Andor DU-897 camera. Images were taken using a ×100/1.40 Oil U Plan S-Apo objective lens. Pre-bleaching and fluorescence recovery images of the eGFP-AR were acquired using a laser power of 488 nm with an exposure time of 100 ms. Bleaching was done in a 10 × 10 pixel square region of interest (ROI) on top of a droplet, which was repeated five times; the maximum laser power intensity was 488 nm, and the dwell time for bleaching was 40 μs. Twenty pre-bleached images and 200 post-bleached images in total were taken at intervals of 180 ms. Post-bleached images were acquired immediately after the bleaching. Mean gray intensity measurements were quantified in three different ROIs in each FRAP experiment: a bleached region, a background region outside the cells and a region spanning the whole cell were drawn to allow normalization of the gray values. Fiji was used to measure it in each ROI using the plot z-axis profile function to extract the intensity data. Exported csv tables were normalized and fitted in EasyFrap software<sup>74</sup> to extract kinetic parameters, such as T-half and mobile fraction. Double normalization was used to correct for fluorescence bleaching during imaging and for differences in intensity.

### Drug-condensate interactions

**Drug partition coefficient calculation.** Concentrations of EPI-001 in the dense and light phases of WT\* AR AD and 8YtoS AR AD were determined using the Agilent Technologies 1200 HPLC instrument, using a Jupiter analytical C4 column from Phenomenex. H<sub>2</sub>O and ACN:H<sub>2</sub>O (9:1) were used as mobile phases, containing 0.1% TFA.

Samples were prepared on ice in 20 mM sodium phosphate buffer (pH 7.4), 1 mM TCEP and 0.05% (wt/wt) NaN<sub>3</sub>. One equivalent of compound was added to 60 μM of protein from DMSO stocks. The final concentration of DMSO in all samples was 2%. Liquid-liquid phase separation of the protein was induced by adding 1.25 M NaCl, followed by incubation for 5 min at 37 °C and centrifugation at 2,000 r.p.m. for 2 min at 37 °C to separate the light and dense phases. The light phase was transferred to a new microcentrifuge tube, and the dense phase was diluted nine times by adding the buffer containing 4 M urea, which dissolved the condensates. These solutions were injected in an HPLC system. The corresponding peaks of small molecules were integrated, and concentrations were determined using standard calibration curves that were obtained by measuring four concentrations for each compound.

**Effect of compounds on AR AD phase separation in vitro.** The effects of compounds on AR AD phase separation in vitro were assessed by



turbidity (see ‘Turbidity measurements’) and microscopy (see ‘Fluorescence microscopy of in vitro protein condensation’). The samples contained 25  $\mu\text{M}$  WT\* AR AD with 1 molar equivalent of the indicated compounds in 20 mM sodium phosphate buffer (pH 7.4), 1 mM TCEP, 0.05% (wt/vol)  $\text{NaN}_3$ , 1 M NaCl and 2% DMSO.

### Experiments in cells

**Luciferase reporter assay in HEK293T.** HEK293T cells were co-transfected with an androgen-response element (ARE)-luciferase construct containing a luciferase reporter gene under the control of three AREs (kindly provided by the M. Pennuto lab), along with an empty vector, an AR-expression vector (pEGFP-C1-AR or AR V7) or different mutants in the presence or absence of DHT. HEK293T cells were maintained in DMEM with 10% charcoal-stripped FBS during the assay. Transfections were carried out using PEI, and cells were treated with vehicle or 1 nM DHT 24 h after transfection. Cell extracts were prepared 48 h after transfection, when eGFP-AR mutants are mostly localized to the nucleus, and assayed for luciferase activity using the Promega luciferase detection kit. Luciferase activities were normalized to co-transfected  $\beta$ -galactosidase activity<sup>81</sup>.

**Luciferase reporter assays in LNCaP.** PSA(6.1 kb)-luciferase, V7BS3-luciferase and AR-V7 plasmids and transfections of cells have been described previously<sup>24,52,53,82</sup>. PSA(6.1 kb)-luciferase reporter plasmid (0.25  $\mu\text{g}$  well<sup>-1</sup>) was transiently transfected into LNCaP cells that were seeded in 24-well plates. Twenty-four hours after transfection, cells were pretreated with compounds for 1 h prior to the addition of 1 nM R1881 and incubation for an additional 24 h. For the V7BS3-luciferase reporter, an expression vector encoding AR-V7 (0.05  $\mu\text{g}$  well<sup>-1</sup>) and a filler plasmid (pGL4.26, 0.45  $\mu\text{g}$  well<sup>-1</sup>) were transiently co-transfected with V7BS3-luciferase reporter plasmid (0.25  $\mu\text{g}$  well<sup>-1</sup>) into LNCaP cells in 24-well plates. After 24 h, the cells were treated with the indicated compounds for additional 24 hours. Transfections were completed under serum-free conditions using Fugene HD (Promega). Luciferase activity was measured for 10 s using the Luciferase Assay System (Promega) and normalized to total protein concentration determined by the Bradford assay. Validation of consistent levels of expression of AR-V7 protein was done using western blot analyses.

**Proliferation assays.** LNCaP cells (Clone FGC, ATCC CRL-1740) in RPMI-1640 with 5% FBS were seeded at a density of 4,000 cells well<sup>-1</sup> into 96-well flat-bottom plates (Greiner, 655075) that had been pre-coated with poly-L-lysine (Sigma P4707). Sixteen hours later, triplicate wells were refreshed with 100  $\mu\text{l}$  of seeding medium spiked with 7 $\times$  serial dilutions of EPI-001 from 200  $\mu\text{M}$  (Selleckchem lot no. S795502), 7 $\times$  serial dilutions of Iae from 50  $\mu\text{M}$ , or DMSO control, at a constant DMSO concentration of 0.5% (vol/vol). Ninety-six hours later, wells were washed with 200  $\mu\text{l}$  PBS and then fixed with 100  $\mu\text{l}$  of 4% PFA in PBS for 20 min at room temperature. After fixation, LNCaP nuclei in each well were counterstained using 100  $\mu\text{l}$  of Hoechst 33342 (Abcam ab228551), diluted to 1:4,000 in PBS, for 20 min at room temperature. After a final wash in PBS, plates were imaged using a CellDiscoverer 7 microscope equipped with a  $\times 20$  air objective. Twenty-five tile regions (5  $\times$  5 tiles) were imaged for each technical replicate well (triplicate wells for each dose and compound). Data were acquired across two biological replicates performed on different weeks.

To compare the antiproliferative effects of Iae and enzalutamide in LNCaP and LNCaP95 cells, LNCaP cells (5,000 cells well<sup>-1</sup>) were plated in 96-well plates in their respective media plus 1.5% dextran-coated charcoal (DCC)-stripped serum. LNCaP cells were pretreated with the compounds for 1 h before they were treated with 0.1 nM R1881 for an additional 3 d. Proliferation and viability were measured using the Alamar blue cell viability assay, following the manufacturer’s protocol (Thermo Fisher Scientific). LNCaP95 cells (6,000 cells well<sup>-1</sup>) were

seeded in 96-well plates in RPMI plus 1.5% DCC for 48 h before the addition of compounds and incubation for an additional 48 h. BrdU incorporation was measured using BrdU Elisa kit (Roche Diagnostics).

**Quantitative real-time polymerase chain reaction.** Target primer sequences are listed in Supplementary Table 6. LNCaP cells (Clone FGC, ATCC CRL-1740) in RPMI-1640 with 5% FBS were seeded at a density of 300,000 cells well<sup>-1</sup> in 6-well plates. Sixteen hours later, wells were refreshed with seeding medium spiked with either EPI-001 or Iae at doses roughly corresponding to the IC<sub>50</sub> and IC<sub>10</sub> values calculated from proliferation assays, indicated in Extended Data Fig. 7a, and 0.5% vol/vol DMSO control. After 6 or 24 h, the medium was removed and cells were collected using 300  $\mu\text{l}$  of TRIzol reagent (Thermo Fisher Scientific 15596026) in each well. RNA was then extracted using a Zymo DirectZol Micro kit (Zymo R2062), according to the manufacturer’s protocol. cDNA was synthesized using 1  $\mu\text{g}$  of RNA, random hexamer primers, and the RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific K1622). cDNA collected from LNCaP cells treated with either EPI-001 or Iae at each dosage, and time point, were then probed for transcript targets on 384-well plates using the SYBR Green master mix (Thermo Fisher Scientific A25777), and a QuantStudio 7 real-time qPCR machine. For calculation of the fold change ( $2^{-\Delta\Delta\text{Ct}}$  method), Ct values from target regions were normalized to Ct values from control regions from the treatment sample, and were then normalized to the DMSO sample. Data were collected from three biological replicates performed on different days.

**RNA-seq data generation.** LNCaP cells (Clone FGC, ATCC CRL-1740) in RPMI-1640 with 5% FBS were seeded at a density of 300,000 cells well<sup>-1</sup> into 6-well plates. Sixteen hours later, wells were refreshed with seeding medium spiked with either EPI-001 or Iae at the doses indicated in Fig. 6c and 0.5% vol/vol DMSO control. After 6 or 24 h, medium was removed and cells were collected using 300  $\mu\text{l}$  of TRIzol (Thermo Fisher Scientific 15596026) in each well. RNA was then extracted using a Zymo DirectZol Micro kit (Zymo R2062), according to the manufacturer’s protocol. Total RNA-seq libraries were then prepared using 1  $\mu\text{g}$  of RNA from each sample and the KAPA RNA HyperPrep Kit with RiboErase (Roche KR1351), according to the manufacturer’s protocol, with ten amplification cycles. Libraries were sequenced on a NovaSeq 6000 with paired-end reads of 100 bp, with a read depth of 50 million fragments per library. Three libraries from three corresponding biological replicates were prepared for each treatment (time, dosage, and compound).

**Western blot.** To compare the levels of AR expression, cells were washed and collected in PBS  $\times 1$  and lysed in RIPA buffer  $\times 1$  (Thermo Fisher Scientific, 88900) containing phosphatase and protease inhibitors (Roche). Lysates were centrifuged at 15,000g to separate soluble and pellet fractions. Total protein was quantified using a BCA assay (Pierce Biotechnology). Proteins were resolved by 4–12% gradient Bis-Tris SDS-PAGE (Invitrogen NP0323), transferred to PVDF membranes and blocked with 5% non-fat milk in TBST for 1 h at room temperature with shaking. The membranes were incubated with the following antibodies: anti-GAPDH (Abcam, ab59164, 1:2,000) and anti-AR (Abcam, ab108341, 1:2,000) as well as RD-680-conjugated anti-mouse (LI-COR, 926-68072, 1:10,000) and CW-800-conjugated anti-rabbit (LI-COR, 926-32211, 1:10,000) secondary antibodies. Membrane fluorescence was read with the Odyssey CLx infrared imaging system (LI-COR).

To determine the effect of Iae treatment on AR levels, LNCaP cells (ATCC, CRL-1740) were seeded in RPMI-1640 (Thermo Fisher Scientific, 11875093) supplemented with 5% FBS (Thermo Fisher Scientific, 1835030) and 1% penicillin–streptomycin (Thermo Fisher Scientific, 15140122) at a density of 150,000 cells well<sup>-1</sup> into six-well plates (Thermo Fisher Scientific, 140685). Forty-eight hours later, cycloheximide (Sigma, C7698) was added to a final concentration

of 50  $\mu\text{g ml}^{-1}$  and incubated for 3 h before incubation with Iae (at the indicated concentrations) for 21 h. Cells were washed in PBS (Thermo Fisher Scientific, 11835030) and lysed in RIPA buffer (Thermo Fisher Scientific, 88900) containing protease inhibitor (Abcam, ab274282). Lysates were centrifuged at 15,000g to separate soluble and insoluble fractions. Soluble protein was quantified using a BCA assay (Pierce Biotechnology, 23225). Protein extracts (10–70  $\mu\text{g}$ ) were electrophoresed in a Bolt 8% Bis-Tris gel (Invitrogen, NW00085BOX) and transferred with PVDF transfer stacks (Invitrogen, PB5210). Membranes were blocked with 3% non-fat milk in TBST for 1 h at room temperature with shaking. Afterwards, membranes were incubated with the following antibodies: anti-GAPDH (Abcam, ab59164, 1:1,000), anti-AR (Abcam, ab108341, 1:1,000), 800-CW-conjugated anti-rabbit (LI-COR, 926-32211, 1:10,000) and RD-680-conjugated anti-mouse (LI-COR, 926-68072, 1:10,000). Imaging was done using the Odyssey CLx, and protein-band intensity was quantified with ImageJ.

**Lentiviral production for FLAG-BioID-AR cell lines.** FLAG-MTID, FLAG-AR-WT-MTID or FLAG-22YtoS-MTID were subcloned from pcDNA3.1(-) (Genscript) into pLenti-CMV-MCS-GFP-SV-puro (Addgene no. 73582) by replacing GFP using XbaI-BamHI digestion. Vectors were co-transfected with lentiviral packaging plasmid vectors REV (cat. no. 12253), RRE (cat. no. 12251) and VSV-G (cat. no. 8454) into 293T cells with PEI (Sigma-Aldrich). Two days after transfection, virus-containing medium was collected and filtered through a 0.45- $\mu\text{m}$  low-protein-binding filtration cartridge. The virus-containing medium was used to directly infect LNCaP/PC3 cells in the presence of polybrene (8  $\mu\text{g ml}^{-1}$ ) for 48 h, before 1  $\mu\text{g ml}^{-1}$  puromycin was introduced for 72 h to select for stable cell lines. pMDLg/pRRE was a gift from D. Trono (Addgene plasmid no. 12251; <http://n2t.net/addgene:12251>; RRID: [Addgene\\_12251](https://identifiers.org/RRID:Addgene_12251)). pCMV-VSV-G was a gift from B. Weinberg (Addgene plasmid no. 8454; <http://n2t.net/addgene:8454>; RRID: [Addgene\\_8454](https://identifiers.org/RRID:Addgene_8454)). pRSV-Rev was a gift from D. Trono (Addgene plasmid no. 12253; <http://n2t.net/addgene:12253>; RRID: [Addgene\\_12253](https://identifiers.org/RRID:Addgene_12253)).

**BioID-MS.** Prior to BioID experiments, MTID-containing stable cell lines were generated through lentiviral infection and puromycin selection. They were subsequently grown in RPMI-1640 medium modified with L-glutamine without phenol red or biotin (United States Biological, R9002-01) with 10% (vol/vol) charcoal-stripped FBS for 48 h. Cells were seeded, and the next day, 50  $\mu\text{M}$  biotin (IBA; 2-1016-002) and 1 nM DHT were added for 2 h. For small-molecule inhibitors, cells were pretreated for 1 h with either EPI-001 or Iae, then for 2 h with DHT and biotin. For MS, cells were collected through trypsinization, washed two times in PBS and snap-frozen on dry ice. Cell pellets were lysed in modified RIPA buffer (1% TX-100, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% SDS, 0.5% sodium deoxycholate and protease inhibitors) on ice and treated with 250 U benzonase (Millipore), and biotinylated proteins were isolated using streptavidin-sepharose beads (GE Healthcare). Proteins were washed in ammonium bicarbonate and digested with trypsin. Mass spectrometry was performed in the IRB Barcelona Mass Spectrometry and Proteomics facility, as described previously<sup>83</sup>. Data were analyzed using SAINTq<sup>84</sup>.

**Proximity ligation assay.** Protein–protein interactions were studied using a Duolink In Situ Orange Starter Kit Mouse/Rabbit (Sigma, DUO92102), following the manufacturer's protocol. Briefly, transduced prostate cancer cells were seeded in coverslips and cultured overnight. The next day, they were treated with 50  $\mu\text{M}$  biotin and 1 nM DHT for 2 h or were pretreated initially with small-molecule inhibitors. Slides were washed with cold 1 $\times$  PBS and fixed in 4% paraformaldehyde for 15 min, washed in PBS and permeabilized using 0.1% Triton X-100 for 10 min and washed then blocked with blocking buffer (3% BSA, 0.1% Tween in PBS) for 1 h at 37 °C. The coverslips were blocked with Duolink Blocking Solution in a pre-heated humidified chamber for 30 min at

37 °C. Primary antibodies to the following proteins were added and incubated overnight at 4 °C: androgen receptor (ER179(2)) (Abcam, no. ab108341, 1:200), Nup153 (Abcam, QE5, no. ab24700, 1:200), Med1 (Abcam, no. ab64965, 1:200) and ARID1a/BAF250A (Cell Signalling, no. 12354, 1/200). Coverslips were then washed with 1 $\times$  wash buffer A and subsequently incubated with the two PLA probes (1:5, diluted in antibody diluents) for 1 h, then the ligation-ligase solution for 30 min, and the amplification-polymerase solution for 100 min in a pre-heated humidified chamber at 37 °C. Before imaging, slides were washed with 1 $\times$  wash buffer B and mounted with a cover slip using Duolink In Situ Mounting Medium with DAPI. Fluorescence images were acquired using a Leica TCS SP8 confocal microscope. Images were taken with  $\times 100$  oil objectives, using standard LAS-AF software.

**Gene expression analysis.** To analyze tumor gene expression, tumors were flash frozen, and -100-mg samples were pulverized under liquid nitrogen. Samples were added to 1 ml TRIzol (Invitrogen) and homogenized using a FastPrep-24 tissue homogenizer (MP Biomedicals). Total RNA was extracted using the RNeasy Micro Kit (Qiagen), cleaned using the DNase I Kit, amplification grade (MilliporeSigma), and reverse transcribed using the High-Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific), according to the manufacturers' protocols. Diluted cDNA and Platinum SYBR Green qPCR SuperMix-UDG with ROX (Invitrogen) were combined with gene-specific primers. Transcript quantification was completed using a QuantStudio 6 RT-qPCR machine, and calculation of the mean normalized expression of target transcripts was done using the  $2^{-\Delta\Delta\text{Ct}}$  method using the housekeeping gene *SDHA*. To analyze gene expression in PC3 cells expressing ARV7,  $2 \times 10^5$  cells were plated in duplicate in 6-well plates. After 48 h, total RNA was extracted using the SV Total RNA Isolation System (Promega), following the manufacturer's instructions.

**Determination of AR levels in LNCaP treated with Iae and CHX.** LNCaP cells (ATCC, CRL-1740) were seeded in RPMI-1640 (Thermo Fisher Scientific, 11875093) supplemented with 5% FBS (Thermo Fisher Scientific, 1835030) and 1% penicillin–streptomycin (Thermo Fisher Scientific, 15140122) at a density of 150,000 cells well<sup>-1</sup> into 6-well plates (Thermo Fisher Scientific, 140685). Forty-eight hours later, cycloheximide (Sigma, C7698) was added to a final concentration of 50  $\mu\text{g ml}^{-1}$  and incubated for 3 h before incubation with Iae (at the indicated concentrations) for 21 h. Cells were washed in PBS (Thermo Fisher Scientific, 11835030) and lysed in RIPA buffer (Thermo Fisher Scientific, 88900) containing protease inhibitor (Abcam, ab274282). Lysates were centrifuged at 15,000g to separate the soluble and insoluble fractions. Soluble protein was quantified using the BCA assay (Pierce Biotechnology, 23225). Protein extracts (10–70  $\mu\text{g}$ ) were electrophoresed in a Bolt 8% Bis-Tris gel (Invitrogen, NW00085BOX) and transferred using PVDF transfer stacks (Invitrogen, PB5210). Membranes were blocked with 3% non-fat milk in TBST for 1 h at room temperature with shaking. Afterwards, membranes were incubated with the following antibodies: anti-GAPDH (ab59164, 1:1,000), anti-AR (ab108341, 1:1,000), 800-CW-conjugated anti-rabbit (LI-COR 926-32211, 1:10,000) and anti-mouse (LI-COR 926-68072, 1:10,000). Imaging was conducted with Odyssey CLx, and protein-band intensity was quantified with ImageJ.

### Molecular dynamics simulation

A molecular dynamics simulation of the AR Tau-5<sub>R2,R3</sub> region (residues L391–G446, capped with ACE and NH<sub>2</sub> groups) in the presence of Iae was performed using GROMACS 2019.2 (refs. 85,86), patched with PLUMED v2.6.0 (ref. 87) as described previously<sup>51</sup> and compared with previously reported simulation results of Tau-5<sub>R2,R3</sub> in the presence of EPI-002 (ref. 51). In brief, an explicit solvent simulation was performed in a cubic box with a length of 7.5 nm and neutralized with a salt concentration of 20 mM NaCl by 8 Na<sup>+</sup> ions and 5 Cl<sup>-</sup> ions. The AR Tau-5<sub>R2,R3</sub> protein was parameterized using the a99SB-disp force field; water

molecules were parameterized with the a99SB-disp water model<sup>88</sup>. 1aa was parameterized using the GAFF<sup>89</sup> for ligand forcefield parameters. The replica exchange with solute tempering (REST2) algorithm<sup>90</sup> was used to enhance conformational sampling. Sixteen replicas were run in parallel using a temperature ladder ranging from 300–500 K, with all protein and ligand atoms selected as the solute region. Tau-5<sub>R2-R3</sub> with 1aa was simulated for 5.2  $\mu$ s per replica, respectively, for a total simulation time of 83.2  $\mu$ s. Convergence of simulated properties was assessed by a comparison of the conformational sampling of each simulated replica, as previously reported<sup>51</sup>, and statistical errors were calculated using a blocking analysis following Flyvbjerg and Peterson<sup>91</sup>. We define an intermolecular contact between a ligand and a protein residue as occurring in any frame where at least one heavy (non-hydrogen) atom of that residue is found within 6.0 Å of a ligand heavy atom. To calculate a simulated  $K_D$  value for each compound, we defined the bound population of each ligand as the fraction of frames with at least one intermolecular contact between a ligand and Tau-5<sub>R2-R3</sub>.

### Statistics and reproducibility

**Statistical analysis.** Pairwise comparisons shown in Figs. 1h, 2d,g, 3e,g, 4k, 5d,f,g,i and 6j,k and Extended Data Figs. 4d,g,h,j,k, 5d, 6c,j,k, 7f and 8a,b were performed using a Student's *t*-test or Mann–Whitney *U* test in base R or python. Differences were considered significant when adjusted *P* values were lower than 0.0001 (\*\*\*\*), 0.001 (\*\*\*) or 0.01 (\*\*) or 0.05 (\*).

**AR  $\Delta$ NLS image analysis in live cells.** A custom-made macro in Fiji was developed to quantify the total number and the size of AR condensates into the cytoplasm as a function of time (Fig. 3e and Extended Data Fig. 4d,g,j,k). This macro also quantifies the total area of the cytosol to normalize the results.

The macro creates zintensity projections of the 3D stacks. A manual step of drawing a ROI was integrated into the macro to select the nuclei to be removed so that only the cytoplasm area would be kept for the detection and quantification of the AR condensates. After filtering and thresholding steps, the cytosol area was segmented and quantified. Then a mathematical operation was done between the resulting mask of the cytosol without the nuclei and the z maximum intensity projection data to detect and quantify the total number and the area of AR condensates in the cytosol. The quantification was done at three time points after DHT exposure.

**AR nuclear translocation rate analysis.** A custom-made macro in Fiji was developed to quantify the mean gray intensity value in the nuclei area over time (Fig. 2b). The macro creates a z-sum projection of the 3D stacks from the time-lapse to improve the quantitiveness of the results. A stackreg plugin is used in the macro to register and correct the xymovement of the cells over time; there is a manual step that involves drawing the nuclei area and the cytoplasm area to extract automatically the mean gray values of these ROIs over time.

**Luciferase reporter assay in HEK293T.** For the transcriptional activity assay, reported in Fig. 2g, a general linear model was used to compare differences in the log-transformed ARE-luciferase/ $\beta$ -galactosidase ratio between groups of interest using biological replicates as covariates. For clarity of representation, ARE-luciferase/ $\beta$ -galactosidase ratios are shown in the original scale.

**Analysis of FRAP data for cell experiments.** Mean intensities of bleached areas were corrected both for bleaching due to imaging over time and background noise. The corresponding calculations were performed with EasyFrap by calculating the fluorescence intensity over time ( $I(t)$ ). Obtained values were further normalized to the initial fluorescence by dividing  $I(t)$  by the mean gray value of the initial pre-bleaching acquisition images.

**Granularity analysis.** Image analysis was assisted by a macro written at the IRB ADMCF. An individual segmentation mask was obtained for each nucleus (excluding the nucleoli) by simple median filtering, background subtraction and local thresholding. Nuclei exhibiting an insufficient or overly strong level of expression were excluded manually, and the s.d. of the intensity was estimated inside the remaining nuclei in the original images. For the granularity analysis, reported in Fig. 2d, the s.d. values were compared across groups by linear regression. The relationship between s.d. and mean intensity was also compared across groups, and is reported in Extended Data Fig. 3a, by fitting a linear model with the s.d. as the response variable and taking the mean intensity, the group, the interaction between the group and the mean intensity and the biological replicate as explanatory variables. The slope between mean intensity and s.d. was compared for every experimental group against the control through the interaction term of the linear model. Dunnett's multiple-comparisons correction was used to compare the linear effects of several experimental groups with a common control. Images of HEK293T cells transfected with mEGFP plasmids, described in Extended Data Fig. 2a, were analyzed using ZEN Blue version 3.2. Image fields were segmented for nuclear regions using automatic thresholding (Otsu thresholding) on the mEGFP channel, and the resulting objects were analyzed for mean intensity and standard deviation of pixels. As above, nuclear clustering (or granularity) was assayed as the s.d. of pixels, and nuclear GFP concentration as the mean intensity of pixels in the corresponding nuclear object. Measurements were exported for data wrangling in R to create the plots shown in Extended Data Fig. 2b. Eight to ten image fields were used to assay nuclei from each condition (transfection and treatment).

**LNCaP dose–response curves.** Raw LNCaP nuclei counts from proliferation experiments, assayed as objects detected by automatic Otsu thresholding on Hoechst signal from image fields from each well (aggregate of 25 tile regions), were used to construct dose–response curves for EPI-001 and 1ae (Fig. 6c). Segmentation was performed using ZEN Blue version 3.2 on image data acquired from two biological replicates. Nuclear counts from each well were exported and processed using the DRC package in R<sup>92</sup> to create the dose–response curves shown in Fig. 6c. Data were modeled with a three-parameter log-logistic function (lower limit 0), and the resulting fit was used to calculate IC<sub>50</sub> and IC<sub>10</sub> values for EPI-001 and 1ae (Fig. 6c).

**In vitro droplet image analysis.** For in vitro droplet analysis of ARAD in images with multiple components in Fig. 1, droplets were identified by applying a threshold (3,255) to the channel sum image using Fiji. AR-AD intensity within the identified droplets larger than 0.1  $\mu$ m across three image fields was extracted and plotted in Fig. 1h. The graph from Fig. 1j was obtained by normalizing each channel's intensity from the plotted profile of a section of a representative droplet using Fiji. Droplets in Fig. 3f were identified applying a threshold (3,255) to the channel sum image using Fiji.

**$\tau$ -STED image analysis.** Composites acquired in  $\tau$ -STED mode (Extended Data Fig. 1b) were exported as .tiff image fields using Leica LAS-X version 2.5.6 and analyzed using a custom Fiji pipeline (Extended Data Fig. 1c), available at <https://github.com/BasuShaoon/AR-RNA-seq-STED>. In brief, the DNA counterstain was first used to identify and threshold nuclear objects. Clusters within nuclear objects were then detected using the rolling ball algorithm, with the size of the rolling ball set to eight times the limit of detection (48 nanometers), according to a standard protocol<sup>93</sup>. This enabled detection of nuclear AR clusters for cells imaged with the same  $\tau$ -deconvolution strength. Nuclear AR clusters were pooled from 7 LNCaP nuclei and analyzed for mean intensity and size as indicated in Extended Data Fig. 1b.

**ChromLogD determination.** ChromLogD values were experimentally determined as a measure of hydrophobicity of the 1aa family of compounds. The experimental evaluation was subcontracted to Fidelta. Values of ChromLogD were calculated from the equation:

$$\text{ChromLogD} = 0.0857 \times \text{CHI} - 2,$$

In which CHI is a chromatographic hydrophobicity index. CHI values were determined from gradient retention times at pH = 7.4. Chromatograms were measured using the Agilent 1100 HPLC instrument, using a Luna C18 analytical column from Phenomenex. For mobile phases, 50 mM ammonium acetate (in H<sub>2</sub>O) and ACN were used, with 0.1% TFA. The chromatographic separation was optimized for a 5-min run, by using a linear gradient from 0% to 100% ACN in the first 3 min.

**RNA-sequencing data pre-processing.** Paired-end sequencing reads were first quality checked using FASTQC and then aligned to the *Homo sapiens* genome build hg19 using STAR aligner v2.7.5a (ref. 94) with standard settings. The first and fourth columns in ReadsPerGene.out.tab STAR output files (GeneIDs and reverse strand reads) were used to build raw count matrices for each sample library.

**Differential expression analysis.** Differential expression analysis between treatment conditions was conducted using the DESeq2R/bioconductor package, a statistical tool that uses shrinkage estimates to compute fold changes<sup>95</sup>. First, raw count matrices from sample libraries were merged into a single object using the 'DESeqDataSetFromHTSeqCount' function with the design set to the treatment condition (time, compound and dosage). The merged count matrix was then fitted to the DESeq statistical model using the 'DESeq' function. The fit and merged matrix was then reduced using a variance-stabilizing transformation, 'vst', to visualize principal components one and two (Extended Data Fig. 7b). The fold change values in gene expression and corresponding significance scores were then extracted using the 'results' function by querying a contrast between any two conditions (Supplementary Data Table 3). Cutoffs of  $|\log_2(\text{FC})| > 1$  and  $P < 1 \times 10^{-10}$  were used to determine differentially expressed genes in a given contrast (Fig. 6d).

**Gene set enrichment analysis.** Gene set enrichment analysis was performed using R/bioconductor packages fgsea and DOSE<sup>96,97</sup>. Ranked gene lists were first constructed using  $\log_2(\text{FC})$  values for the genes in any given DESeq2 contrast by sorting  $\log_2(\text{FC})$  values in descending order and filtering out duplicate entries. Ranked lists were then analyzed for the enrichment of 50 hallmark gene sets (collection H) obtained from the molecular signature database msigDB, maintained by the Broad Institute, using the 'plotEnrichment' and 'plotfgseaRes' functions in fgsea and the 'GSEA' function in DOSE (nperm = 10,000, Pvalue cutoff < 0.05).

Besides the commonly used gene set enrichment plot for a queried gene pathway (Extended Data Fig. 7c,e) we also show enrichment scores for the top 10 negatively and top 10 positively enriched pathways as a dotplot, with gradient scaling to the normalized enrichment score (red, positive NES; blue, negative NES) and size proportional to the statistical significance ( $P_{\text{adj}}$ ) of the calculated enrichment (Fig. 6e).

For the analysis of AR V7 mutants (Extended Data Fig. 3j–l), AR target genes upregulated in PC3 cells were identified using a composite of AR GSEA data sets<sup>96</sup>.

**Mean expression value of genes in hallmark gene sets.** Line plots for mean expression values of genes were adapted from refs. 98,99. In brief, reads from the merged count matrix were normalized using the equation  $\log_2(\text{normalized DESeq counts} + 1)$  to create a  $\log_2$  normalized count matrix (Supplementary Data Table 4). Normalized counts for each gene in the matrix were then z-score-scaled using the 'scale\_rows'

function from the pheatmap R package. Code integrated with DESeq2 available at <https://github.com/BasuShaon/AR-RNA-seq-STED>. Values of the genes from the below gene sets were then plotted as indicated in Fig. 6f and Extended Data Fig. 7d as a function of the concentration of EPI-001 and 1ae. MsigDB hallmark pathway set H: <http://www.gsea-msigdb.org/gsea/msigdb/genesets.jsp?collection=H>. EPI-001 negative DEGs: KLK3, ADAM7, TBX15, FKBP5, PGC, LAMA1, ELL2, CHRNA2, STEAP4, DSC1, UGT2B28, TNS3, BMPR1B, SLC38A4, EAF2, TTN, SLC15A2, CCDC141, HPGD, TMEM100, MAF, F5, TRGC1.

## Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

## Data availability

The RNA-sequencing data have been deposited in the NCBI GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) under accession codes GSE206853 and GSE232849. The NMR assignments for constructs 441–558 and the AR AD have been deposited in the BMRB (<https://bmr.io/>) with accession codes 51476 and 51480, respectively. The molecular dynamics simulation trajectories, GROMACS input files and analysis code have been deposited in Zenodo (<https://doi.org/10.5281/zenodo.8210256>). Source data are provided with this paper.

## Code availability

Molecular dynamics simulation analysis code is freely available from Github: [https://github.com/paulrobustelli/Basu\\_Rational\\_Optimization\\_AR\\_inhibitors\\_NSMB\\_2023](https://github.com/paulrobustelli/Basu_Rational_Optimization_AR_inhibitors_NSMB_2023). Code for gene expression analyses is also freely available from Github: <https://github.com/BasuShaon/AR-RNA-seq-STED>.

## References

- Piol, D. et al. Antagonistic effect of cyclin-dependent kinases and a calcium-dependent phosphatase on polyglutamine-expanded androgen receptor toxic gain of function. *Sci. Adv.* **9**, eade1694 (2023).
- Kumar, S. & Tyagi, R. K. Androgen receptor association with mitotic chromatin—analysis with introduced deletions and disease-inflicting mutations. *FEBS J.* **279**, 4598–4614 (2012).
- Chan, S. C., Li, Y. & Dehm, S. M. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. *J. Biol. Chem.* **287**, 19736–19749 (2012).
- Pesarrodona, M., Latorre, I. & Salvatella, X. Intrinsically disordered proteins (IDP): purification under denaturing conditions. *Methods Mol. Biol.* **2406**, 359–370 (2022).
- Alberti, S. et al. A user's guide for phase separation assays with purified proteins. *J. Mol. Biol.* **430**, 4806–4820 (2018).
- Rapsomaniki, M. A. et al. easyFRAP: an interactive, easy-to-use tool for qualitative and quantitative analysis of FRAP data. *Bioinformatics* **28**, 1800–1801 (2012).
- Solyom, Z. et al. BEST-TROSY experiments for time-efficient sequential resonance assignment of large disordered proteins. *J. Biomol. NMR* **55**, 311–321 (2013).
- Yuwen, T. & Skrynnikov, N. R. CP-HISQC: a better version of HSQC experiment for intrinsically disordered proteins under physiological conditions. *J. Biomol. NMR* **58**, 175–192 (2014).
- Orekhov, V. Y. & Jaravine, V. A. Analysis of non-uniformly sampled spectra with multi-dimensional decomposition. *Prog. Nucl. Magn. Reson. Spectrosc.* **59**, 271–292 (2011).
- Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR* **6**, 277–293 (1995).
- Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. *Proteins* **59**, 687–696 (2005).

80. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).
81. Palazzolo, I. et al. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. *Hum. Mol. Genet.* **16**, 1593–1603 (2007).
82. Ueda, T., Bruchovsky, N. & Sadar, M. D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. *J. Biol. Chem.* **277**, 7076–7085 (2002).
83. Pavinato, L. et al. Functional analysis of TLK2 variants and their proximal interactomes implicates impaired kinase activity and chromatin maintenance defects in their pathogenesis. *J. Med. Genet.* **59**, 170–179 (2022).
84. Teo, G. et al. SAINTq: scoring protein–protein interactions in affinity purification–mass spectrometry experiments with fragment or peptide intensity data. *Proteomics* **16**, 2238–2245 (2016).
85. Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX* **1–2**, 19–25 (2015).
86. Páll, S., Abraham, M. J., Kutzner, C., Hess, B. & Lindahl, E. in *Solving Software Challenges for Exascale 3–27* (Springer International Publishing, 2015).
87. Tribello, G. A., Bonomi, M., Branduardi, D., Camilloni, C. & Bussi, G. PLUMED 2: new feathers for an old bird. *Comput. Phys. Commun.* **185**, 604–613 (2014).
88. Robustelli, P., Piana, S. & Shaw, D. E. Developing a molecular dynamics force field for both folded and disordered protein states. *Proc. Natl Acad. Sci. USA* **115**, E4758–E4766 (2018).
89. Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. *J. Comput. Chem.* **25**, 1157–1174 (2004).
90. Wang, L., Friesner, R. A. & Berne, B. J. Replica exchange with solute scaling: a more efficient version of replica exchange with solute tempering (REST2). *J. Phys. Chem. B* **115**, 9431–9438 (2011).
91. Flyvbjerg, H. & Petersen, H. G. Error estimates on averages of correlated data. *J. Chem. Phys.* **91**, 461–466 (1989).
92. Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose–response analysis using R. *PLoS ONE* **10**, e0146021 (2015).
93. Sternberg, R. Biomedical image processing. *Computer* **16**, 22–34 (1983).
94. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
95. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
96. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550 (2005).
97. Yu, G., Wang, L.-G., Yan, G.-R. & He, Q.-Y. DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis. *Bioinformatics* **31**, 608–609 (2015).
98. Lovén, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell* **153**, 320–334 (2013).
99. Sormanni, P., Aprile, F. A. & Vendruscolo, M. The CamSol method of rational design of protein mutants with enhanced solubility. *J. Mol. Biol.* **427**, 478–490 (2015).
- Hnisz and Salvatella laboratories for helpful discussions. We thank A. Honingmann (MPI-CBG) for help with image analysis, R. Buschow (MPI-MG) for introduction to STED microscopy and H. Kretzmer (MPI-MG) for advice on bioinformatics analyses. We acknowledge help and support from the advanced digital microscopy, high-throughput protein expression and mass spectrometry, biostatistics/bioinformatics and sequencing core facilities at MPI-MG and IRB. Finally, we acknowledge help and support from the Spanish ICTS Red de Laboratorios de RMN de biomoléculas (R-LRB). B.M. was supported by the AECC (POSTD211371MATE). M.B. was supported by a Marie Curie PREBIST grant (754558). T.H.S. was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health (ZIA BC 012012). P.R. and J.Z. were supported by the National Institutes of Health under award R35GM142750; J.Z. was also supported by the China Scholarship Council. M.D.S. acknowledges funding from the National Cancer Institute of the National Institutes of Health (R01CA105304 and R01CA255044). The work was also supported by an ASPIRE I Award from the Mark Foundation for Cancer Research (to D.H.). X.S. was supported by AGAUR (2017 SGR 324), MINECO and MICINN (BIO2015-70092-R and PID2019-110198RB-I00), the Fundació La Caixa (CI20-00098), the AECC (INNO20010FRIG) and the European Research Council (CONCERT, contract number 648201). A.R. and X.V. were supported by MICINN (PID2020-115074GB-I00). IRB Barcelona is the recipient of a Severo Ochoa Award of Excellence from MINECO (Government of Spain).

## Author contributions

Conceptualization: S. Basu, P.M.-C., M.F.-V., M.P., M.D.S., A. Riera, D.H. and X.S.; Methodology: S. Basu, P.M.-C., M.F.-V., M.P., E.S., M.L., S. Bielskuté, J.Z., K.P.-G., L.B., A. Ruffoni and D.M.; Investigation and formal analysis: S. Basu, P.M.-C., M.F.-V., M.P., E.S., M.L., C.A.B., C.S.-Z., S. Bielskuté, J.Z., C.G.-C., L.Z., H.D., J.S., H.K., C.B., M.B., A.E., N.R.M., J.W., J.K.O. and T.T.; Software: S. Basu and M.L.; Supervision: B.M., X.V., I.B.-H., S.V., J.G., P.R., T.H.S., M.D.S., A. Riera, D.H. and X.S.; Writing, original draft: S. Basu, P.M.-C., D.H. and X.S.; Writing, review and editing: all authors. Funding acquisition: P.R., T.H.S., M.D.S., A.Ri., D.H. and X.S.

## Competing interests

M.F.-V. is an employee of Dewpoint Therapeutics. M.P., M.L., L.Z., H.D. and M.B. are employees of Nuage Therapeutics. M.B., D.H. and X.S. are founders of Nuage Therapeutics. D.H. and X.S. are scientific advisors of Nuage Therapeutics. The remaining authors declare no competing interests.

## Additional information

**Extended data** is available for this paper at <https://doi.org/10.1038/s41594-023-01159-5>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41594-023-01159-5>.


**Correspondence and requests for materials** should be addressed to Marianne D. Sadar, Antoni Riera, Denes Hnisz or Xavier Salvatella.

**Peer review information** *Nature Structural & Molecular Biology* thanks Luca Magnani and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Sara Osman was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team. Peer reviewer reports are available.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).


## Acknowledgements

We thank T. Mittag (St Jude Children’s Research Hospital), C. Helsen and F. Claessens (University of Leuven), D. Presman and G. Hager (NCI-NIH), and the members of the Bulut-Karslioglu,



**Extended Data Fig. 1 | Characterization of AR condensates in cells using high resolution microscopy.** **a)** (left) Live-cell stimulated emission depletion (STED) imaging of a HeLa cell nucleus expressing AR-eGFP, treated with 1 nM DHT for 4 h (right)  $\tau$ -STED imaging of endogenous AR in fixed human prostate adenocarcinoma (LNCaP) cells. Large scale bars: 5  $\mu$ m. Scale bar in  $\tau$ -STED inset: 300 nm. Dashed line indicates the nuclear periphery. **b)** (top) Quantification of  $\tau$ -STED intensity signal and (bottom) diameter of endogenous AR clusters in LNCaP cells (1750 AR clusters detected across 7 LNCaP nuclei imaged with same fluorescence time gating). L.o.d indicates the limit of detection. Densitymax diameter (bin with highest density of AR clusters in the distribution of all

detected AR clusters): 123 nm, median diameter: 178 nm. **c)** Quantification pipeline used to analyze STED image composites, showing segmentation of cells and detection of clusters using rolling ball background subtraction adjusted to 8 x the resolving capacity of the image (48 nm pixel<sup>-1</sup> for TauSTED imaging of LNCaP cells). **d)** Representative ( $n > 3$ ) STED (top row) and FLIM STED images showing AR clusters in LNCaP nuclei before and after  $\tau$ -STED deconvolution (middle and bottom row). Left column shows LNCaP nuclear counterstain using Spy555-DNA stain. Scale bar: 5  $\mu$ m. Right panels show zoom-ins corresponding to intra-nuclear regions indicated by white boxes on panels in the central column. Scale bar: 500 nm.



Extended Data Fig. 2 | See next page for caption.

**Extended Data Fig. 2 | AR phase separation is driven by tyrosine residues**

**in the AD. a**) Live-cell confocal imaging of constructs in HEK293T cells after treatment with vehicle or 10 nM DHT for 4 h. Scale bar: 3  $\mu\text{m}$ . Dashed lines indicate nuclear periphery. **b**) Quantification of data in panel A. Y-axis indicates s.d. and x-axis indicates mean intensity of pixels in the corresponding nucleus. Each dot represents measurements from an individual cell, and lines represent standard regression fits to the corresponding data spread ( $n = 2$ ). **c**) Distribution of aromatic and tyrosine residues, clustered using a 9 residue window, where the shaded areas correspond to those represented in Fig. 1c. **d**) Average intensity of the resonances at different concentrations, relative to their intensity at 25  $\mu\text{M}$ , grouped by residue type. **e**) Solubility predicted by CamSol for peptides FQNLFQ (black line) and FQNPFQ (red line)<sup>99</sup>. **f**) Representative ( $n > 3$ ) TEM micrographs of peptides FQNLFQ and FQNPFQ after an overnight incubation. **g**) Synchronous light scattering of peptides FQNLFQ (black line) and FQNPFQ (red line) after an overnight incubation. **h**) FT-IR absorbance spectrum in the


amide I region (dashed line) of the aggregates formed by the FQNLFQ peptide. The blue shaded area indicates the contribution of the intermolecular  $\beta$ -sheet signal. **i**) Fluorescence microscopy images of ARAD (WT\*) droplets in 20 mM sodium phosphate, 1 mM TCEP pH 7.4 with 150 mM NaCl and 10% ficoll. Scale bar: 10  $\mu\text{m}$ . **j**) DIC images showing fusion events of 50  $\mu\text{M}$  ARAD WT or WT\* samples at 500 mM NaCl at times before and/or after 5 min from sample preparation. **k**) Fluorescence intensity recovery curves shown as average and s.d. ( $n = 3$  independent samples) and quantification of the recovery half-time and mobile fraction (average  $\pm$  s.d.,  $n = 4$  and  $n = 8$  droplets for WT and L26P (WT\*) respectively) and representative confocal microscopy images. **l**) (Left) Droplets formed by the indicated proteins and signals of the ARAD channel and merged channel. ARAD proteins were used concentrations 5 times higher than in Fig. 1i. Scale bar: 1  $\mu\text{m}$ . (Right) the representative droplet's cross-section intensity profile.





**Extended Data Fig. 3 | Tyrosine to serine mutations decrease AR granularity, translocation and alter its interactome. a, b** Representative ( $n > 3$ ) images of PC3 cells expressing eGFP-AR (A) and eGFP-AR V7 (B). **c** Expression levels of transfected PC3 cells with eGFP-AR constructs and endogenous levels of AR in LNCaP and LNCaP95 cells. GAPDH was used as loading control. **d** Quantification of the granularity (s.d.) as a function of the mean nuclear intensity. **e** Western blot of FLAG-MTID-AR or FLAG-MTID-Y22toS proteins in PC3 cells. **f, g** Scatter plot of the protein intensities at  $t_{\text{DHT}} = 0$  and 60 min for PC3 cells expressing FLAG-MTID-WT-AR (F) and FLAG-MTID-22YtoS (G) following SAINTq analysis. Proteins with a BFDR  $\leq 0.05$  are shown (gray circle) and those with a BFDR  $\leq 0.02$  and/or FC  $\geq 3$  in  $t_{\text{DHT}} = 60$  min are highlighted in blue and red. **h** Enriched gene ontology molecular function (GO-MF) categories in FLAG-MTID-WT-AR and FLAG-MTID-22YtoS samples ( $t_{\text{DHT}} = 60$  min). The 75 most abundant proteins, with a cutoff of BFDR  $\leq 0.02$  and FC  $\geq 3$ , were analyzed using STRING and GO

categories. The  $-\log_{10}(\text{FDR})$  for selected categories are shown: those highlighted in Fig. 2e are in bold (Supplementary Data Table 1. i) Venn diagrams showing proteins identified in WT and 22YtoS (top), WT and AR interactions reported in BioGRID and Y22toS and AR interactions reported in BioGRID. Number of proteins identified ( $t_{\text{DHT}} = 0$  and 60 min) with a BFDR  $\leq 0.02$  and a FC  $\geq 3$  in bold and numbers of proteins identified with a BFDR  $\leq 0.05$  in gray (Supplementary Data Table 1). **j** Gene expression in AR-V7 mutants: heatmap of  $\log_2$  fold changes ( $\log_2\text{FC}$ ) compared to the empty vector transduced control PC3 line (Supplementary Data Table 5). Selected genes shown are a composite of several GSEA 'AR up' genesets (Broad Institute) upregulated by AR V7 in PC3 cells. **k, l** Scatter plots of the selected genes comparing 22YtoS (**k**) or 22YtoF (**l**) to WT AR V7 according to a one-tailed  $t$ -test comparing calculated NES to the permuted null distribution, with  $P$ value adjustment using Benjamini-Hochberg procedure.




Extended Data Fig. 4 | See next page for caption.

**Extended Data Fig. 4 | Transactivating units and motifs with helical propensity in AR AD contribute to condensation of AR in vitro and in cells.**


**a)** Schematic model describing the nuclear translocation pathway of eGFP-AR and cytoplasmic retention of eGFP-AR- $\Delta$ NLS upon exposure to ligand (DHT). **b, c)** Time-lapse fluorescence microscopy of eGFP-AR (A) and eGFP-AR- $\Delta$ NLS (B) condensates upon treatment with 1 nM dihydrotestosterone (DHT) in transiently transfected PC3 cells. Scale bar: 10  $\mu$ m. Dashed line indicates the nuclear periphery. **d)** Distributions of average condensate size and density. Each dot corresponds to the mean values measured in an individual cell ( $n = 45$  cells). *P* values are from Mann-Whitney U tests. n.s.: not significant. **e)** Snapshots at the indicated time points highlighting a fusion event of eGFP-AR- $\Delta$ NLS condensates in the cytoplasm of a PC3 cell. Scale bar: 1  $\mu$ m. **f)** Fluorescence recovery after photobleaching (FRAP) analysis of cytoplasmic eGFP-AR- $\Delta$ NLS condensates in PC3 cells 1 hour and 24 h after addition of 1 nM DHT ( $t_{\text{DHT}} \approx 1$  h). Average relative

fluorescence intensity curve of the eGFP-AR- $\Delta$ NLS cytoplasmic condensates as a function of time is shown. Error bars represent s.d. of  $n = 34$  condensates per time point. Within the box, representative images of condensates before and after photobleaching are shown. Scale bar: 1  $\mu$ m. **g)** Effect of the mutations introduced in Tau-1 and Tau-5 on the density of the cytosolic condensates formed by eGFP-AR- $\Delta$ NLS as a function of  $t_{\text{DHT}}$  in PC3 cells. Each dot corresponds to a cell ( $n > 20$  cells). *P* values are from a Mann-Whitney U test. **h)** Effect of deleting the region of sequence of the AD containing the  $^{23}\text{FQNLQ}^{27}$  motif on the cytosolic condensates formed by eGFP-AR- $\Delta$ NLS upon addition of DHT. Scale bar: 10  $\mu$ m. The dashed line indicates nuclear periphery. **i, j)** Effect of deleting the region of sequence of the AD containing the  $^{23}\text{FQNLQ}^{27}$  motif on the distribution of average droplet size (I) and droplet density (J) of the cytosolic condensates formed by eGFP-AR- $\Delta$ NLS as a function of  $t_{\text{DHT}}$ , where each dot corresponds to a cell ( $n > 20$  cells). *P* values are from Mann-Whitney U tests.




**Extended Data Fig. 5 | Characterisation of small molecules with enhanced potency.** **a**) Inhibition (average  $\pm$  s.e.m.,  $n = 3$ ) of the androgen-induced full-length AR transcriptional activity by compounds shown in Fig. 4a. **b**) Selected regions of Tau-5\*  $^1\text{H}$ ,  $^{15}\text{N}$  BEST-TROSY spectra in the absence (gray) and presence of 1 mol equivalent of EPI-001 (blue) and 1aa (red). **c**) Helical propensities of Tau-5R2\_R3 in its apo form (black) and in bound conformations obtained from simulations run in the presence of EPI-002 (blue) and 1aa (red) with an indication of the positions of helical motifs and aromatic residues in the sequence. The data was obtained from the 300 K REST2 MD simulations. Values are presented as averages  $\pm$  statistical errors from block averaging. **d**) Populations of aromatic stacking contacts between aromatic side chains of Tau-5R2\_R3 and aromatic rings of EPI-002 (blue) and 1aa (red) with an indication of the positions of helical motifs and aromatic residues. The data was obtained from the 300 K REST2 MD simulations. Values are presented as averages  $\pm$  statistical errors from block

averaging. **e**) ChromLogD values of compounds developed from 1aa scaffold reporting their hydrophobicity ( $n = 3$ ). **f**) Comparison of EPI-002 (35  $\mu\text{M}$ ) and enzalutamide (ENZA, 5  $\mu\text{M}$ ) with the most potent compounds (5  $\mu\text{M}$ ) to block AR-V7 transcriptional activity (average  $\pm$  s.e.m.,  $n = 3$ ). **g**, **h**) Lack of a dose-dependent inhibition of AR-V7 transcriptional activity for 1ab (**g**) and 1bb (**h**). LNCaP cells that ectopically expressed AR-V7 were co-transfected with a V7BS3-luciferase reporter gene construct and incubated with the indicated concentrations of the compounds (average  $\pm$  s.e.m.,  $n = 3$ ). **i**, **j**) 1aa blocked the proliferation of both LNCaP cells in response to androgen and AR-V-driven proliferation of LNCaP95 cells whereas Enzalutamide (ENZA) blocked androgen-induced proliferation driven by full-length AR in LNCaP cells but had poor potency against AR-V-driven proliferation of LNCaP95 (LNCaP95) cells (average  $\pm$  s.e.m.,  $n = 3$ ).



**Extended Data Fig. 6 | Small molecule inhibitors alter AR proteomic interactions with Mediator.** **a**) Representative ( $n = 2$ ) western blot showing expression of FLAG-MTID-AR or FLAG-MTID-Y22toS proteins in LNCaP cells with antibodies for AR. Biotin-dependent labeling is shown with Streptavidin antibodies (Strep) and GAPDH and Ponceau staining are shown as loading

controls. EV indicates the empty vector expressing FLAG-MTID. **b**) BioID MS of LNCaP MTID-AR-WT interaction with Mediator complex. Colour indicates strength of interaction from FLAG,  $\text{Log}_{10}$  Tmean of intensity. **c**) TMean SAINTq intensity of total mediator interactions were compared across LNCaP MTID-AR-WT with DMSO or treated cells with small molecule inhibitors.




Extended Data Fig. 7 | See next page for caption.

**Extended Data Fig. 7 | Iae inhibits AR dependent oncogenic pathways in models of CRPC. a)** qRT-PCR of PSA and FKBP5 transcript targets using two primer pairs for each locus. Values indicate  $2^{-\Delta\Delta Ct}$  (Log fold change in target signal versus  $\beta$ -Glucuronidase housekeeping gene signal normalized to values from corresponding DMSO control sample, average  $\pm$  s.e.m.,  $n = 3$ ). **b)** Principal component analysis of LNCaP cells treated with EPI-001 or Iae ( $n = 3$ ). **c)** Sequential walk of the GSEA running enrichment score of hallmark androgen response pathway genes in LNCaP cells treated with EPI-001 or Iae, versus DMSO, for 24 h. Top 5 downregulated genes for EPI-001 and Iae treatment contributing to the leading edge indicated in top right, and adjusted  $P$ value of GSEA statistic indicated in bottom left ( $n = 3$ ) according to a one tailed  $t$ -test comparing calculated NES to the permuted null distribution, with  $P$ value adjustment using Benjamini-Hochberg procedure. **d)** Line plots of mean normalized, log transformed read counts of significantly depleted gene sets in

LNCaP cells treated with EPI-001 or Iae versus DMSO at 24 h (shown in Fig. 6e), as a function of concentration. Light lines represent individual genes, dark lines represent average of all genes, and bars represent s.d. ( $n = 3$ ). **e)** GSEA analysis of RNA-seq experiment showing most significantly activated and suppressed pathways for EPI-001 and Iae treatment, vs DMSO, at 24 h, ranked by the adjusted  $P$ value ( $padj$ ). Gene pathways split by 'activated' or 'suppressed' based on GSEA enrichment in the gene list ranked by  $\log_2 FC$  vs DMSO, in order of gene ratio (detected genes/all genes in pathway) of the analyzed pathway. Circles scale to the count of detected genes from the pathway, and color scales to  $padj$  from the pathway ( $n = 3$ ), according to a one tailed  $t$ -test comparing calculated NES to the permuted null distribution, with  $P$ value adjustment using Benjamini-Hochberg procedure. **f)** Quantification of AR signal, versus DMSO control, normalized to GAPDH signal from western blots of LNCaP cells treated with CHX for 3 h, then Iae at indicated concentrations for 21 h ( $n = 3$ , except 5 and 10  $\mu M$  where  $n = 2$ ).





**Extended Data Fig. 8 | 1ae has on-target activity in LNCaP and LNCaP95 xenografts.** Real-time PCR of AR, KLK2, KLK3, FKBP5, NKX3.1, and ALAS1 transcript normalized to SDHA harvested from LNCaP tumors (a), and AR, AR-V7, CCNA2, UBE2C, B4GALT1 and ALAS1 transcript normalized to SDHA harvested from LNCaP95-D3 tumors (b). Both enzalutamide and 1ae show on target

activity and do not affect expression of housekeeping gene ALAS1 in LNCaP xenografts. Conversely only 1ae is capable of repressing AR-V7 induced genes, or de-repressing AR-V7 repressed gene B4GALT1. Error bars represent s.e.m. of  $n = 3$  samples per treatment arm.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a                                 | Confirmed  |
|-------------------------------------|--|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of all covariates tested  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated   |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

**Data collection** NMR data was acquired with TOPSPIN 4.0.8 (Bruker) and processed with NMRPipe 212\_64 and qMDD 3.2. FTIR data was acquired with OPUS MIR Tensor 27. MD simulations were run with GROMACS 2019.270-72 patched with PLUMED v2.6.0. RNA-seq data was quality-checked with FASTQC 0.11.9 and aligned to the Homo sapiens genome hg19 with STAR aligner v.2.7.5a with standard settings.

**Data analysis** NMR data was analyzed with CcpNmr Analysys 2.4.2 and delta2D (online). FTIR data was analyzed with Peak Fit 4.2. Live cell microscopy data was analyzed with Fiji imaging software (ImageJ 1.52p), LAS-AF and LAS-X (2.5.6, Leica). FRAP data was analyzed with EasyFRAP (online). BioID-MS data was analyzed with SAINTq. The images used for the granularity were analyzed with ZEN Blue 3.2. The LNCaP dose response curves were processed with the DRC package in R. MD trajectories were analyzed with python packages MDtraj, numpy and pyblock. The differential expression analysis was conducted with the DESeq2 R/bioconductor package and the gene set enrichment with packages fgsea and DOSE.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The RNA-sequencing data has been deposited in the NCBI GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) with accession codes GSE206853 and GSE232849. The NMR assignments for constructs 441-558 and the AR AD have been deposited in the BMRB (<https://bmr.io/>) with accession codes 51476 and 51480, respectively. The molecular dynamics simulation trajectories, GROMACS input files, and analysis code have been deposited in Zenodo (<https://doi.org/10.5281/zenodo.8210256>). The raw data used to produce all figures is available as Source Data files.

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender

Not relevant to this study

Population characteristics

Not relevant to this study

Recruitment

Not relevant to this study

Ethics oversight

Not relevant to this study

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

No statistical method was used to determine sample size. Sample size was determined by the number of relevant experimental observations e.g. number of cells, and always larger than 1.

Data exclusions

No data was excluded in the studies.

Replication

Biological replicates were used in all experiments in cells.

Randomization

Randomization was considered not necessary in this study.

Blinding

Blinding was considered not necessary in this study.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials &amp; experimental systems

n/a	Involvement
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

## Methods

n/a	Involvement
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

## Antibodies used

Androgen Receptor [ER179(2)] Abcam Cat#ab108341  
 Streptavidin antibody, Alexa Fluor™ 488 conjugate ThermoScientific Cat #S11223  
 Alexa Fluor 488 Goat anti-Rabbit IgG (H+L) ThermoScientific Cat #A11008  
 Androgen Receptor (441) SCBT Cat #sc-7305  
 STAR 635P Abberior Cat #ST635P-1001  
 Goat anti-Rabbit IgG (H+L) Secondary Antibody, HRP Invitrogen Cat #65-6120  
 Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP Invitrogen Cat #G-21040  
 Nup153 antibody (QE5) Abcam Cat #ab24700  
 Med1 antibody Abcam Cat #ab64965  
 ARID1A/BAF250A (D2A8U) CellSignal #12354  
 GADPH Abcam Cat#ab59164  
 anti-mouse RD-680 conjugated LI-COR CatR #926-68072  
 anti-rabbit CW-800 conjugated LI-COR CatR #926-32211

## Validation

All antibodies used in this study are commercial, validated by the manufacturer for the relevant applications and widely used, as described in the following websites:

<https://www.abcam.com/products/primary-antibodies/androgen-receptor-antibody-er1792-chip-grade-ab108341.html>  
<https://www.thermofisher.com/order/catalog/product/es/en/S11223>  
<https://www.thermofisher.com/antibody/product/Goat-anti-Rabbit-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11008>  
<https://www.scbt.com/p/ar-antibody-441>  
<https://abberior.shop/abberior-STAR-635P>  
<https://www.thermofisher.com/antibody/product/Goat-anti-Rabbit-IgG-H-L-Secondary-Antibody-Polyclonal/65-6120>  
<https://www.thermofisher.com/antibody/product/Goat-anti-Mouse-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/G-21040>  
<https://www.abcam.com/products/primary-antibodies/nup153-antibody-qe5-ab24700.html>  
<https://www.abcam.com/products/primary-antibodies/trap220med1-antibody-ab64965.html>  
<https://www.cellsignal.com/products/primary-antibodies/arid1a-baf250a-d2a8u-rabbit-mab/12354>  
<https://www.abcam.com/products/primary-antibodies/gapdh-antibody-ff26a-ab59164.html>  
<https://www.licor.com/bio/reagents/irdye-680rd-donkey-anti-mouse-igg-secondary-antibody>  
<https://www.licor.com/bio/reagents/irdye-800cw-goat-anti-rabbit-igg-secondary-antibody>

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

## Cell line source(s)

HEK293T cells ATCC CRL-3216  
 PC3 cells ATCC CRL-1435  
 LNCaP clone FGC ATCC CRL-1740  
 LNCaP95-D3 Leung et al., 2021 (generated by the laboratory of M. D. Sadar)  
 Hela AR-eGFP 24Q Piol et al., 2023 (generated by the laboratory of M. Pennuto)

## Authentication

None of the cells were authenticated

## Mycoplasma contamination

All cell lines tested negative

Commonly misidentified lines  
(See [ICLAC](#) register)

No commonly misidentified cell lines were used in this study.

## Animals and other research organisms

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

## Laboratory animals

Six to eight-weeks-old male mice (NOD-scid IL2Rgammanull).

Wild animals

No wild animals were used in this study.

Reporting on sex

Findings apply to only male animals

Field-collected samples

Not field collected samples were used in this study.

Ethics oversight

University of British Columbia Animal Care Committee (A18-0077)

Note that full information on the approval of the study protocol must also be provided in the manuscript.